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GAS is the most common cause of bacterial pharyngitis in children and adolescents. It accounts for 15 to 30 percent
of all cases of pharyngitis in children between the ages of 5 and 15 years (up-to-date, 2016), and peaks at 7 to 8
years of age. The incidence of GAS pharyngitis is highest during the winter and early spring. During these seasons,
GAS causes up to 35 to 40 percent of cases of pharyngitis in children and adolescents (Up-to-date, 2016). GAS
pharyngitis is most common in school-age children but may occur in younger children, especially if they have close
contact with school-age children. Prevalence of GAS among school-aged children who present to an outpatient clinic or
emergency department with sore throat is around 37 percent. The prevalence among children <5 years is around 24
percent (Up-to-date, 2016). Up to 70% of patients with sore throats seen in primary care receive prescriptions for
antimicrobials, while only 20-30% are likely to have GAS pharyngitis (Shulman, 2012).
Definition: Group A Streptococcus (GAS), also known as Streptococcus pyogenes, is a gram-positive coccus that
grows in chains.
Objective of Guideline: Update providers on appropriate diagnostics and therapy for pediatric patients with
streptococcal pharyngitis. The Clinical Practice Guideline will standardize care and improve health outcomes in
pediatric patients with streptococcal pharyngitis by establishing care standardization focused on diagnosis, initiation of
treatment and proper follow up.
Target population: Pediatric patients
Key stakeholders and users:
•
Doctors
•
Advanced Practice Nurses
•
Direct Care Nurses
•
Laboratory
•
Patients and Families
Guideline Inclusion Criteria:
•
Suspected GABH streptococcus
•
>Age 3 years
Guideline Exclusion Criteria:
Concern for the following
o Peritonsillar abscess
o Lymphadenitis* (tender, swollen lymph nodes with overlying erythema)
o Viral stomatitis
o Retropharyngeal abscess (such as restricted neck movement secondary to pain)
o Ludwig’s angina (cellulitis of the floor of the mouth)
Setting:
•
Emergency Department
•
Urgent Care
•
Primary Care
Measures:
Outcome:
1) Recommended antibiotic (penicillin or amoxicillin; cephalexin for penicillin allergy) utilization and
length/dose (Length of enteral antibiotic treatment and dose)
2) Clinically indicated laboratory testing (Decrease the number of unnecessary rapid streptococcal antigen
tests)
Process:
1) Power Note utilization
2) Power Plan utilization (CPG Coverage)
3) Family education
4) Provider knowledge
Balance:
1) Readmit with the same diagnosis within 2 weeks
Potential Cost Implications:
1) Decreased lab tests
2) Decreased antibiotic costs
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Potential Barriers:
1) Providers grounded in traditional standard of care
2) Parental insistence to obtain rapid strep screen, antibiotics for viral sore throat
Supporting Tools:
•
Power Plan (to be completed)
•
Algorithm (to be completed)
Existing documents:
•
IDSA Guideline 2012
•
Judicious Use of Antibiotics for Streptococcal Pharyngitis
For all clinical questions, the Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal
Pharyngitis: 2012 Updated by the Infectious Disease Society of America (IDSA) was adopted as our “parent” guideline.

The Guideline was assessed using the AGREE II Tool by four reviewers. For each domain contains three to eight
questions, that are answered on a numeric scale, range [1-7], higher is better.
AGREE II Tool Score:
Domain

Domain 1 - SCOPE AND PURPOSE
Domain 2 - STAKEHOLDER INVOLVEMENT
Domain 3 - RIGOR OF DEVELOPMENT
Domain 4 - CLARITY AND PRESENTIATION
Domain 5 - APPLICABILITY
Domain 6 - EDITORIAL INDEPENDENCE
Overall Guideline Assessment

Percent
Agreement
96%
74%
74%
76%
53%
63%
73%

Clinical Questions Answered by Guideline:
1) In pediatric patients, are there any valid and reliable clinical scoring of pharyngitis Centor criteria or other
criteria? (Critical) (see Appendix A)
2) In pediatric patients, how often do adverse side effects occur with antibiotic therapy (Rash, nausea, vomiting, &
diarrhea)? (Critical) (see Appendix B)
3) In pediatric patients with streptococcal pharyngitis, do oral antibiotics versus intramuscular injections result in
faster clinical cure? (Critical) (see Appendix C)
4) In pediatric patients with streptococcal pharyngitis, is amoxicillin versus other antibiotics more efficacious for
clinical cure? (Critical) (see Appendix D)
5) In pediatric patients, what is the incidence of streptococcal pharyngitis under three years of age? (Important)
(see Appendix E)
6) In pediatric patients with streptococcal pharyngitis, how soon can patients return to school after starting
antibiotics? (Important) (see Appendix F)

Practice Recommendations:
Diagnostic Evaluation:
1. Clinical prediction rules for identifying the pediatric patient with group A streptococcal (GAS) pharyngitis are
not recommended due to their low diagnostic accuracy (see Appendix A)
2. Do not test patients with viral the following symptoms (if viral etiology strongly suggested; provide
symptomatic care and do not test):
a. Cough
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b. Hoarseness
c. Coryza (rhinorrhea/nasal congestion)
d. Conjunctivitis
e. Viral exanthem
f. Mouth ulcers
g. Diarrhea
Perform Rapid Antigen Detection Test (RADT) if patient has one or more exam finding consistent with
streptococcal pharyngitis
a. Exam finding consistent with streptococcal pharyngitis:
i. Tonsillopharyngeal erythema
ii. Tender anterior cervical nodes
iii. Scarlitinform rash
iv. Tonsillar exudate
v. Palatal petechiae
vi. Swollen red uvula
b. Associated symptoms of streptococcal pharyngitis include:
i. Abdominal pain
ii. Headache
Testing children <3 years old is generally not indicated unless they present with signs and symptoms
consistent with strep throat and have household contact with an individual with a positive rapid antigen
streptococcal test or culture (see Appendix E)
Streptococcal pharyngitis typically presents in winter/spring
Fever is often present, but fever alone without sore throat makes streptococcal pharyngitis unlikely
Exclusion Criteria:
a. Peritonsillar abscess
b. Lymphadenitis (tender, swollen lymph nodes with overlying erythema)
c. Retropharyngeal abscess (such as restricted neck movement secondary to pain)
d. Ludwig’s angina (cellulitis of the floor of the mouth)

Diagnostics:
1. Rapid Antigen Detection Test (RADT)
a. Start antibiotic treatment if positive
b. If negative, do not treat with antibiotics and await reflex culture, provide symptomatic care
i. If reflex culture is negative, provide symptomatic care
ii. If reflex culture is positive, start antibiotic treatment
Treatment:
1. Preferred treatment:
a. Amoxicillin 50mg/kg/dose once daily for 10 days, Max Dose: 1gm
b. Children and adolescents ≥40kg; 1000mg once daily for 10 days
c. The cure rate of amoxicillin is as high as other antibiotics (see Appendix D)

2. Alternative Choice: Oral or IM benzathine penicillin
a.
b.
c.
d.
e.

Penicillin VK ≤27kg: 250 mg PO every 12 hours, for 10 days
Penicillin VK ≥27kg: 500 mg PO every 12 hours, for 10 days (max single dose 500mg)
Bicillin L-A ≤27 kg: 600,000 units IM x 1
Bicillin L-A >27 kg: 1.2 million units IM x 1
The cure rate for oral and IM penicillin are both equivocal (see Appendix C)

3. Non-severe penicillin allergy (hives)
a.

Cephalexin 50mg/kg/day divided BID for 10day (max 1000mg/day)

4. Serious penicillin allergy (anaphylaxis)
a.

Clindamycin 30mg/kg/day divided TID for 10days (max 900mg/day)

5. The use of antibiotics is not without side effects and clinicians should make parents aware of the harm-tobenefit ratio of taking antibiotics. For every 14 children treated with antibiotics, one child will have an
adverse event such as vomiting, diarrhea, or rash (see Appendix B)
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6. Therapies not recommended
a.
b.
c.

Aspirin
Glucocorticoids
Following antibiotic classes:
i. Fluoroquinolones
1. Levofloxacin
2. Ciprofloxacin
3. Moxifloxacin
ii. Tetracyclines
1. Tetracycline
2. Minocycline
3. Doxycycline
iii. Sulfa
a. Sulfamethoxazole / Trimethoprim
iv. 2nd and 3rd generation cephalosporins (unnecessarily broad spectrum)
v. Macrolides are not recommended unless severe allergy to penicillin and cephalosporins
exist. Resistance is well known and treatment failures related to macrolide resistance have
occurred.

7. Children can return to School or childcare within 12 to 24 hours after starting antibiotics (see Appendix F)
Complications of:
1. Pharyngitis caused by group A streptococcus (GAS) is usually a self-limited condition; symptoms in
untreated patients typically last two to five days. Antimicrobial therapy reduces the duration and severity
of symptoms by one to two days and prevents spread of infection (Pichichero, 2017)
2. Potential complications of GAS pharyngitis
a. Nonsuppurative complication
i. Acute rheumatic fever (ARF)
1. The incidence of acute rheumatic fever (ARF) in the United States is ≤2 cases per
100,000 school-aged children (Beaudoin et al., 2015)
ii. Acute glomerulonephritis
1. The incidence of clinically detectable glomerulonephritis in children infected during an
epidemic is about 5 to 10 percent with pharyngitis (Pichichero, 2017)
iii. Scarlet Fever
1. The incidence of scarlet fever is estimated to be 0.3 cases per 1000 per year
(Pichcherio, 2017)
iv. Poststreptococcal arthritis (PSRA)
v. Streptococcal toxic shock syndrome
b. Suppurative complications
i. Peritonsillar abscess
1. The incidence of pediatric retropharyngeal abscess ranged from .1 case/10,000 in
2000 to .22/10,000 (Van Brusselen et al., 2014)
ii. Mastoiditis
iii. Otitis Media
1. GAS accounts for less than 5 percent of all cases of acute otitis media (Pinchero,
2017).
iv. Sinusitis
v. Necrotizing fasciitis
vi. Streptococcal bacteremia
vii. Meningitis
Guideline Preparation: This guideline was prepared by The Office of Evidence Based Practice (EBP) in collaboration
with content experts at Children’s Mercy Hospitals and Clinics. Development of this guideline supports the Department
of Clinical Effectiveness’s initiative to promote care standardization that builds a culture of quality and safety that is
evidenced by measured outcomes. If a conflict of interest is identified the conflict will be disclosed next to the team
members name.
Strep Pharyngitis CPG Team Members:
• Angela Myers, MD, MPH – Team Lead

5

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Office of

•
•
•

April 2018
Laura Norton, MD – Team Lead
Marilyn Hamilton, MD, PhD
Christine Scoby, DO
Irina Trifonova, MD
Tania Ahluwalia, MD
Shobhit Jain, MD
Abigail Hardin, MD
Ashley Fletcher, MD
Jessica Costalez, MD
Kerri Wade, MSN, RD, PPZCNP-BC
Debbie Jaklevic, MSN, APRN, FNP-C, CPN
Juhi Kangas, MD
Diana Yu, PharmD
Anne Wirtz, PharmD
Alaina Burns, PharmD
Vanessa Watkins, MPH, FACHE, CHES (Patient advocate)
Amy Scott MSN, RN, CPN
Allison Burris, MD
EBP Team Members:
Jeffrey Michael, DO – Evidence Based Practice Medical Director
Jacqueline Bartlett, PhD, RN – Evidence Based Practice Director
Jarrod Dusin, MS, RD, LD, CNSC – Evidence Based Practice Program Manager; Team Facilitator

Guideline development funded by:
No external funding was obtained in the development of this guideline.
Development Process:
Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Updated by
the Infectious Disease Society of America was identified as a mother guideline. The AGREE II tool was used to
determine the quality the guidelines. A further literature search was preformed to look for any new literature that
included systematic reviews, meta-analyses, and other published guidelines on the subject of our questions.
The review summary documents the following steps:
1. Review of existing internal and external guidelines and standards
a. Internal guidelines: Judicious Use of Antibiotics for Streptococcal Pharyngitis
b. External guidelines: Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal
Pharyngitis: 2012 Update by the Infectious Disease Society of America
2. Review preparation
a. PICOT questions established
b. Team leaders confirmed search terms used
3. Databases searched
a. AHRQ National Guideline Clearinghouse
b. Medline
c. Cochrane
d. CINAHL
4. Critically analyze the evidence
a. Guidelines
i.
AGREE criteria were used to analyze published clinical guidelines
b. Literature
i.
CASP tools were used to analyze the literature (e.g. study limitations, consistency of results, directness
of evidence, precision and reporting bias)
ii.
GRADE criteria evaluated the literature based on:
1.The balance between desirable and undesirable effects
2.Patient values and preferences
3.Resource utilization
The table below defines how the quality of the evidence is rated and how the recommendation is
established based on the type of evidence:
Quality
Type of Evidence
High
Consistent evidence from well-performed RCTs or
exceptionally strong evidence from unbiased
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observational studies.
Moderate
Evidence from RCTs with important limitations
(inconsistent results, methodological flaws, indirect
evidence, or imprecise results) or unusually strong
evidence from unbiased observational studies.
Low
Evidence for at least 1 critical outcome from
observational studies, from RCTs with serious flaws or
indirect evidence.
Very Low
Evidence for at least 1 of the critical outcomes from
unsystematic clinical observations or very indirect
evidence.
Recommendation
Type of Evidence
Strong
Desirable effects clearly outweigh undesirable effects or
vice versa
Weak
Desirable effects closely balanced with undesirable effects
5. Recommendations for the guideline were developed by a consensus process incorporating the three principles of
EBP (current literature, content experts, and patient and family preference [when possible])
Approval Process: Guidelines are reviewed and approved by external reviewer Laura Salitros, D.O., Content Expert
Team, the Office of EBP, and other appropriate hospital committees as deemed suitable for the guidelines intended
use. Guidelines are reviewed and updated as necessary every 5 years within the Office of EBP at CMH&C. Content
expert teams will be involved with every review and update.
Disclaimer:
The content experts and the Office of EBP are aware of the controversies surrounding the management of pediatric
patients with streptococcal pharyngitis. When evidence is lacking or inconclusive, options in care are provided in the
guideline and the power plans that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different and those individuals involved in providing health care are expected to use their judgment in determining
what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly,
these guidelines should guide care with the understanding that departures from them may be required at times.
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Appendix A:
Question 1: In pediatric patients, are there any valid and reliable clinical prediction rules for of pharyngitis?
Question Originator: Strep Pharyngitis CPG Team
Plain Language Summary:
The Infectious Diseases Society of America (IDSA) guideline recommends rapid antigen detection tests (RADT) and/or cultures because clinical features
alone do not reliably discriminate between GAS and viral pharyngitis except when overt viral features like rhinorrhea, cough, oral ulcers, and/or hoarseness
are present (Shulman et al., 2012).
Five clinical prediction rules, or scores were reviewed: McIsaac, Breese, Wald, Attia, and Centor. The prediction rules used similar strategies of
recommending “no RADT and no antibiotics” for low scores and “antibiotic with no RADT” with high scores. None of the scores showed significant
diagnostic accuracy to recommend their use (see Tables 1-9). All scores had a high rate of false positive diagnosis for GAS, which would lead to
unnecessary antibiotic treatment. The scores would result in a false positive diagnosis for GAS between 6 and 29%. Clinical prediction rules are unable to
identify patients at low or high risk in whom testing for GAS could be avoided.
The McIsaac score showed the best ability of ruling patients out for having GAS but would result in a large number of false positive patients (see Table 1-3).
The Attia score showed the best ability of ruling patients in for having GAS, although these results were based off one study (see Table 8 & 9).
Literature Summary:
A strong recommendation is made against the use of clinical prediction rules for identifying GAS pharyngitis due to their low diagnostic accuracy. This
recommendation is based on very low-quality evidence and further research could influence our confidence in the results.
Fourteen studies were identified for the clinical prediction rules review. From these 14 studies, nine prediction rules were identified, of which five of the
rules proved to be validated (Cohen et al., 2015). The five clinical prediction rules, with validated studies, were reviewed. The quality of the overall
evidence was very low due to serious risk of bias (Figure 1) along with the body of evidence ranging from serious to very serious for the attributes of
indirectness, inconsistency, and imprecision (see Tables 1-9).
The different prediction rules recommended similar interventions based on the outcome of the applied rules: low scores recommended “no RADT and no
antibiotics”, medium scores “antibiotics with positive test”, and high scores “antibiotic treatment with no RADT” (J. F. Cohen et al., 2015). All the studies
had high risk of bias for their index tests due to the inherent bias of subjective clinical scoring (Ebell, Smith, Barry, Ives, & Carey, 2000). Only the studies
validating the McIsaac score of ≥4 were pooled due to the low number of studies identified for the other prediction rules.
McIsaac Score
Seven diagnostic studies were identified for this clinical prediction rule (Ba‐Saddik et al., 2014; J. F. Cohen et al., 2015; Edmonson & Farwell, 2005; Mazur,
Bochyńska, Juda, & Kozioł-Montewka, 2014; McIsaac & Goel, 1998; McIsaac, Goel, To, & Low, 2000; Walker, Rimoin, Hamza, & Steinhoff, 2006). McIsaac
uses the clinical predictors of: (a) temperature >38 degrees, (b) no cough, (c) tender anterior cervical adenopathy, (d) tonsillar swelling or exudate, and
(e) age. Each predictor is given a score of one point. The suggested course of action for the summated scores are: 0-1, no RADT no antibiotic treatment; 23, antibiotics with positive test result; ≥4, no testing, antibiotics treatment.
Total Score: Three studies (n=932) reported on the total score (Table 1) (J. F. Cohen et al., 2015; McIsaac & Goel, 1998; McIsaac et al., 2000). The
positive predictive value (PPV) ranged from 55-66%, the negative predictive value (NPV) ranged from 94-97%, with the sensitivity ranging from 9397%, and the specificity ranging from 54-72%. Using the McIsaac score would result in 17.5-29 false positive results per 100 patients. False positive
tests would result in unnecessary antibiotic therapy.
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Score ≥4: Five studies (n=2646) evaluated diagnostic accuracy for patients with scores ≥4, see Table 2 (Ba‐Saddik et al., 2014; Edmonson & Farwell,
2005; Mazur et al., 2014; McIsaac & Goel, 1998; Walker et al., 2006). If a patient had a score ≥4 the PPV was 57%. Pooled sensitivity was 0.66, 95%
CI [0.41 to 0.85]. Pooled specificity was 0.70, 95% CI [0.37 to 0.91]. A patient score of ≥4 would result in 18.6 false positive results per 100 patients.
Score <2: Two studies (n=1234) evaluated the sensitivity of patients with scores <2 (J. F. Cohen et al., 2012; Edmonson & Farwell, 2005). Of the two
studies only one (n=785) evaluated specificity (Table 3) (J. F. Cohen et al., 2012). The negative predictive value ranged from 82-89%. Patients with
scores <2 would result in 7-14 false negative results per 100 patients. False negative tests would result in not providing antibiotic therapy to patients.
Breese Score
Four diagnostic studies were identified that analyzed this clinical prediction rule. (Breese, 1977; J. F. Cohen et al., 2012; J. F. Cohen et al., 2015; Ulukol,
Günlemez, Aysev, & Cin, 1999; Walker et al., 2006). Breese uses the clinical predictors of: (a) month in which the patient is seen, (b) age, (c) leukocyte
count, (d) fever, (e) sore throat, (f) cough, (g) headache, (h) abnormal pharynx, and (i) abnormal cervical nodes. The suggested course of action for the
scores are <25: no RADT, no antibiotic treatment; 26-31: antibiotics with positive RADT results; ≥32: no testing, antibiotics treatment prescribed.
Breese total score: Cohen et al. (2012) (n=676) reported on the total score (see Table 4). The PPV was 74% while the NPV was 92%. The sensitivity
was 0.88, 95% CI [0.84 to 0.92] and the specificity was 0.82, 94% CI [0.78 to 0.86]. Use of the Breese score would result in 11.3 false positives
results per 100 patients.
Breese >30: Three studies (n=2394) reported scores greater than 30 (see Table 5) (Breese, 1977; Ulukol et al., 1999; Walker et al., 2006). When
patients had a Breese score >30 the PPV was 60%. There was a large amount of inconsistency with the sensitivity ranging from 28-83%. This score
would also result in 6.9-20.8 false positives results per 100 patients.
Wald Score
Three diagnostic studies were identified for this clinical prediction rule (J. F. Cohen et al., 2015; Wald, Green, Schwartz, & Barbadora, 1998; Walker et al.,
2006). Wald uses the clinical predictors of: (a) age, (b) fever, (c) adenopathy, (d) pharyngitis, and (e) no upper respiratory symptoms. The suggested
course of action for the scores are ≤1: no rapid antigen detection testing (RADT), no antibiotics treatment; 2-4: antibiotic with positive RADT ≥5: no
testing, antibiotic treatment.
Wald total score: One study (n=676) reported on the total score (see Table 6) (J. F. Cohen et al., 2015). The PPV was 60% while the NPV was 95%.
The sensitivity was 0.94, 95% CI [0.91 to 0.97] and the specificity was 0.63, 95% CI [0.58 to 0.68]. The use of the Wald score would result in 20.226.5 false positive results per 100 patients and 1.1-3.3 false negative results per 100 patients.
Wald ≥5: Two studies (n=775) reported scores greater than or equal to five (see Table 7) (Wald et al., 1998; Walker et al., 2006). When patients had
a Wald Score ≥5 the PPV was 43-58%. There was very serious inconsistency with the sensitivity (0.52 to 0.92) and the specificity (0.28 to 0.78) from
these studies. This score would result in 14-45 false positive per 100 patients.
Attia Score
Two diagnostic studies were identified for the Attia clinical prediction rule (Attia, Zaoutis, Klein, & Meier, 2001; J. F. Cohen et al., 2015). Attia uses the
clinical predictors: of (a) scarlatiniform rash, (b) moderate to severe tonsillar swelling, (c) moderate to severe tenderness and enlargement of cervical
lymph nodes, and (d) absence of moderate to severe coryza. The suggested course of action for the scores are: 0, no rapid antigen detection testing, no
antibiotics treatment; 1-3, antibiotic with positive test result ≥4, no testing necessary, antibiotic treatment.
Attia total score: Cohen et al. (2015) (n=676) reported on the total score (see Table 8). The PPV was 81% and the NPV was 92%. The sensitivity was
0.87, 95% CI [0.83 to 0.91] and the specificity was 0.88, 95% CI [0.85 to 0.91]. The use of the Attia Score would result in 7.6 false positive results per
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100 patients and 4.8 per 100 false negative patients.
Attia Score ≥4: Attia et al. (2001) (n=545) reported scores greater than or equal to four (Table 9) (Attia et al., 2001). When a patient had a score of
≥4 the PPV was 83%. These results are based on very low quality of evidence. This results in 0.6-3.8 false positive results per 100 patients.
Centor Score: Three studies were identified that applied the Centor score to children (Orda et al., 2016; Roggen, van Berlaer, Gordts, Pierard, & Hubloue,
2013; Walker et al., 2006) with suspected GAS. Centor uses the clinical predictors of: (a) temperature >38 degrees, (b) no cough, (c) tender anterior
cervical adenopathy, and (d) tonsillar swelling or exudate. Each predictor is given a score of one point. The suggested course of action for the scores are: 01, no RADT, no antibiotic treatment; 2-3, antibiotics with positive RADT; 4: no testing, antibiotic treatment prescribed.
The three studies were not combined due to difference in reporting. Sensitivity and specificity for “total score” and “scores of 4” were not reported in the
three studies. Roggen et al. (2013) preformed a retrospective cohort study from a tertiary university hospital in Brussels (N=441). They reported that a
Centor score of ≥3 was ineffective in ruling in or out GAS (Negative Likelihood ratio 0.67, 95% CI [0.50 to 0.90]; Positive likelihood ratio 1.37, 95% CI
[1.04 to 1.79]. Orda et al. (2016) performed a prospective diagnostic study in a remote Australian emergency department on pediatric patients aged 3-15
(N=101). The area under the receiver operating characteristic (ROC) curve was 0.70, 95% CI [0.58 to 0.81]. The study reported that Centor score was
inadequate for clinical decision-making for children. Walker et al. (2006) reviewed the different clinical prediction rules with 410 children in Egypt. A Centor
score of ≥3 would have resulted in 67 patients (16.3%) with a false positive diagnosis of GAS.

Search Strategy and Results: pharyngitis[tw] AND ("centor"[tw] OR "clinical prediction rule*"[tw] OR "diagnostic criteria"[tw] OR "McIsaac"[tw]) AND
(child[tw] OR childr*[tw] OR childh*[tw] OR adolescen*[tw] OR pediatr*[tw] OR paeditr*[tw]) AND ("Comparative Study" [Publication Type] OR "Validation
Studies as Topic"[Mesh] OR "Validation Studies" [Publication Type] OR "Evaluation Studies" [Publication Type] OR diagnosis OR valid OR validation OR score
OR scale) AND pharyngitis[tw] AND ("centor"[tw] OR "clinical prediction rule*"[tw] OR "diagnostic criteria"[tw] OR "McIsaac"[tw]) AND (child[tw] OR
childr*[tw] OR childh*[tw] OR adolescen*[tw] OR pediatr*[tw] OR paeditr*[tw])
Studies included in this review:
Attia et al., 2001
Ba‐Saddik et al., 2014
Breese, 1977
J. F. Cohen et al., 2012
J. F. Cohen et al., 2015
Edmonson & Farwell, 2005
Mazur et al., 2014
McIsaac & Goel, 1998
McIsaac et al., 2000
Orda et al., 2016
Roggen et al., 2013
Ulukol et al., 1999
Wald et al., 1998
Walker et al., 2006
Studies not included in this review with rationale for exclusion:
Author

Reason for exclusion
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R. Cohen et al., (2004)
McIsaac, et al., (2004)
Tanz et al., (2009)
Fine, Nizet, & Mandl., (2012)
Shih, Lin, & Lu., (2012)

No sensitivity and specificity
No sensitivity and specificity
Combined scores do not match question
No sensitivity and specificity
Low prevalence of 10%

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.3) was used to synthesize the 14 included studies.
Higgins, J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cohcrane Collaboration, 2011.
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Jarrod Dusin, MS, RD, LD, CNSC
Date Developed: July 2017
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Included

Eligibility

Screening

Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b

Records identified through
database searching
(n = 170)

Additional records identified
through other sources
(n = 7)

Records after duplicates removed
(n = 177)

Records screened
(n =177)

Records excluded
(n = 158)

Full-text articles assessed
for eligibility
(n =19)

Full-text articles excluded,
with reasons
(n =5)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 14)

b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Table 1
Question: Should McIsaac be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

0.93 to 0.97

Specificity

0.54 to 0.72

Outcome

№ of studies
(№ of
patients)

True positives
3 studies
(patients with Streptococcal 932 patients
Pharyngitis)

Prevalence 37%

Factors that may decrease quality of evidence
Study design
Risk of
bias
cross-sectional
(cohort type
accuracy study)

serious

a

Indirectness Inconsistency Imprecision

Publication
bias

serious

none

b

not serious

not serious

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

Effect per
1,000 patients
tested
pre-test
probability of
37%
343 to 359

Test
accuracy

⨁⨁◯◯
LOW

11 to 27

3 studies
932 patients

cross-sectional
(cohort type
accuracy study)

serious

a

serious

b

serious

c

serious

d,e

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

340 to 455

175 to 290

Explanations
a. Inherent bias of symptom scoring
b. Assessment scores could be applied differently for the intended populations (patients from different countries than intended guideline)
c. Unexplained inconsistency in sensitivity
d. Wide confidence intervals for specificity 54-72%
e. 17.5% of patients will have a false positive

Table 2

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Question: Should McIsaac Score ≥4 be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

0.66 (95% CI: 0.41 to 0.85)

Specificity

0.70 (95% CI: 0.37 to 0.91)

Outcome

True positives
(patients with Streptococcal
Pharyngitis)

№ of
studies (№
of patients)

5 studies
2646
patients

False negatives
(patients incorrectly classified
as not having Streptococcal
Pharyngitis)
True negatives
(patients without Streptococcal
Pharyngitis)
False positives
(patients incorrectly classified
as having Streptococcal
Pharyngitis)

4 studies
2197
patients

Prevalence 37%

Factors that may decrease quality of evidence
Study
design
Risk of bias
cohort &
casecontrol
type
studies

serious

cohort &
casecontrol
type
studies

serious

a,b

Indirectness

Inconsiste
ncy

Imprecisio
n

serious

serious

serious

c,d

e

f

Publication
bias
none

Effect per
1,000 patients
tested
pre-test
probability of
37%
245 (152 to
313)

Test
accuracy

⨁◯◯◯
VERY
LOW

125 (57 to
218)

a,b

serious

c,d

serious

g

serious

f

none

444 (232 to
571)
186 (59 to
398)

Explanations
a. Patient sampling could have introduced bias
b. Inherent bias of symptom scoring
c. Patient populations are from different countries
d. Assessment scores could be applied differently for the intended populations (patients from different countries than intended guideline)
e. Unexplained inconsistency in sensitivity
f. 35% of patients with a score 4 or greater will have a false positive
g. Unexplained inconsistency in specificity

Table 3
Question: Should McIsaac <2 be used to rule out streptococcal pharyngitis in pediatric patients?

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Sensitivity

0.62 to 0.80

Specificity

0.96 to 0.99

Outcome

True positives
(patients with
Streptococcal Pharyngitis)

№ of studies
(№ of
patients)

Prevalence 37%

Factors that may decrease quality of evidence
Study design
Risk of
bias

2 studies
cross-sectional
1234 patients (cohort type
accuracy study)

very
serious

Indirectness Inconsistency Imprecision

Publication
bias

serious

none

c

not serious

serious

d

pre-test
probability of
37%
229 to 296

a,b

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

Effect per
1,000 patients
tested

Test
accuracy

⨁◯◯◯
VERY
LOW

74 to 141

1 studies
785 patients

cross-sectional
(cohort type
accuracy study)

serious

b

serious

c

not serious

not serious

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

605 to 624

6 to 25

Explanations
a. Edmonson et. al, only used rapid antigen-detection tests as reference standard
b. Inherent bias of symptom scoring
c. Assessment scores could be applied differently for the intended populations (patients from different countries than intended guideline)
d. Wide confidence intervals of 62-80%

Table 4
Question: Should Breese score be used to diagnose streptococcal pharyngitis in pediatric patients?

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁⨁◯◯
LOW

Sensitivity

0.88 (95% CI: 0.84 to 0.92)

Specificity

0.82 (95% CI: 0.78 to 0.86)

Outcome

Factors that may decrease quality of evidence

№ of studies
(№ of
patients)

True positives
1 studies
(patients with Streptococcal 676 patients
Pharyngitis)

Prevalence 37%

Study design
Risk of
bias
cross-sectional
(cohort type
accuracy study)

serious

a

Indirectness Inconsistency Imprecision

Publication
bias

not serious

none

serious

b

not serious

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

pre-test
probability of
37%
326 (311 to
340)

Test
accuracy

⨁⨁◯◯
LOW

44 (30 to 59)

1 studies
676 patients

cross-sectional
(cohort type
accuracy study)

serious

a

not serious

serious

b

serious

c

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

517 (491 to
542)
113 (88 to
139)

Explanations
a. Inherent bias of symptom scoring
b. Only one study looked at Breese total score
c. 11% of patients will have a false positive

Table 5
Question: Should Breese Score >30 be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

Effect per
1,000 patients
tested

0.28 to 0.83

Prevalence 37%

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Specificity

0.67 to 0.89

№ of studies
(№ of
patients)

Outcome

True positives
(patients with
Streptococcal Pharyngitis)

3 studies
2394
patients

Effect per
1,000 patients
tested

Factors that may decrease quality of evidence
Study
design

cohort &
case-control
type studies

Risk of
bias
serious

a

Indirectness
serious

b,c

Inconsistency
very serious

d

Imprecision
not serious

Publication
bias
none

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

pre-test
probability of
37%
104 to 307

⨁◯◯◯
VERY
LOW

63 to 266

3 studies
2394
patients

cohort &
case-control
type studies

serious

a

serious

b,c

serious

e

not serious

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

422 to 561

69 to 208

Explanations
a. Inherent bias of symptom scoring
b. Patients populations are from different countries
c. Assessment scores could be applied differently for the intended populations (patients from different countries than intended guideline)
d. Unexplained inconsistency with sensitivity, with wide confidence interval of CI 28-83%
e. Unexplained inconsistency with specificity

Table 6
Question: Should Wald Score be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

Test
accuracy

0.94 (95% CI: 0.91 to 0.97)

Prevalence 37%

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Specificity

0.63 (95% CI: 0.58 to 0.68)

Outcome

№ of studies
(№ of
patients)

True positives
1 studies
(patients with Streptococcal 676 patients
Pharyngitis)

Factors that may decrease quality of evidence
Study design
Risk of
bias
cross-sectional
(cohort type
accuracy study)

serious

a

Indirectness Inconsistency Imprecision

Publication
bias

not serious

none

serious

b

not serious

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

Effect per
1,000 patients
tested
pre-test
probability of
37%
348 (337 to
359)

Test
accuracy

⨁⨁◯◯
LOW

22 (11 to 33)

1 studies
676 patients

cross-sectional
(cohort type
accuracy study)

serious

a

not serious

serious

b

serious

c

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

397 (365 to
428)
233 (202 to
265)

Explanations
a. Inherent bias of symptom scoring
b. Only one study looked at Wald total score
c. 23% of patients will have a false positive result

Table 7
Question: Should Wald Score >5be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

0.52 to 0.92

Specificity

0.28 to 0.78

Prevalence 37%

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Outcome

True positives
(patients with Streptococcal
Pharyngitis)

№ of studies
(№ of
patients)

2 studies
775 patients

Factors that may decrease quality of evidence
Study design

Risk of
bias

cohort & case- serious
a
control type
studies

Indirectness Inconsistency Imprecision
serious

b,c

serious

d

not serious

Publication
bias
none

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

Effect per 1,000
patients tested
pre-test
probability of
37%
192 to 340

Test
accuracy

⨁◯◯◯
VERY
LOW

30 to 178

2 studies
775 patients

cohort & case- serious
a
control type
studies

serious

b,c

serious

e

serious

f

none

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

176 to 491

139 to 454

Explanations
a. Inherent bias of symptom scoring
b. Patient populations are from different countries
c. Assessment scores could be applied differently for the intended populations (patients from different countries than intended guideline)
d. Unexplained inconsistency for sensitivity
e. Unexplained inconsistency with specificity
f. 14% of patients will have a false positive

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁◯◯◯
VERY
LOW

Table 8
Question: Should Attia score be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

0.87 (95% CI: 0.83 to 0.91)

Specificity

0.88 (95% CI: 0.85 to 0.91)

Outcome

№ of studies
(№ of
patients)

True positives
1 studies
(patients with Streptococcal 676 patients
Pharyngitis)

Prevalence 37%

Factors that may decrease quality of evidence
Study design
Risk of
bias
cross-sectional
(cohort type
accuracy study)

serious

Indirectness Inconsistency Imprecision
not serious

serious

b

not serious

Publication
bias
none

a

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis)
True negatives
(patients without
Streptococcal Pharyngitis)

Effect per
1,000 patients
tested
pre-test
probability of
37%
322 (307 to
337)

Test
accuracy

⨁⨁◯◯
LOW

48 (33 to 63)

1 studies
676 patients

cross-sectional
(cohort type
accuracy study)

serious

not serious

serious

b

not serious

none

a

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis)

554 (536 to
573)
76 (57 to 94)

Explanations
a. Inherent bias of symptom scoring
b. Only once study looked at Attia total score

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁⨁◯◯
LOW

Table 9
Question: Should Attia Score >4 be used to diagnose streptococcal pharyngitis in pediatric patients?
Sensitivity

0.17 (95% CI: 0.13 to 0.27)

Specificity

0.98 (95% CI: 0.94 to 0.99)

Outcome

True positives
(patients with Streptococcal
Pharyngitis )

№ of studies
(№ of
patients)

1 studies
545 patients

Prevalence 37%

Factors that may decrease quality of evidence
Study design

cross-sectional
(cohort type
accuracy study)

Risk of
bias
serious

Indirectness Inconsistency Imprecision
not serious

serious

b

serious

c

Publication
bias
none

pre-test
probability of
37%
63 (48 to 100)

a

False negatives
(patients incorrectly
classified as not having
Streptococcal Pharyngitis )
True negatives
(patients without
Streptococcal Pharyngitis )

Effect per 1,000
patients tested

Test
accuracy

⨁◯◯◯
VERY LOW

307 (270 to
322)

1 studies
545 patients

cross-sectional
(cohort type
accuracy study)

serious

not serious

serious

b

not serious

none

a

False positives
(patients incorrectly
classified as having
Streptococcal Pharyngitis )

617 (592 to
624)
13 (6 to 38)

Explanations
a. Inherent Bias of symptom scoring
b. Only one study looked at Attia Scores >4
c. 31% of patients would have a false negative with a score greater than 4

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

⨁⨁◯◯
LOW

Figure 1: Risk of Bias

Figure 2: McIsaac Total Score

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Figure 3: McIsaac ≥4

Figure 4: McIsaac ≤2

Figure 5: Breese Total Score

Figure 6: Breese >30

Figure 7: Wald ≥5

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Figure 8: Attia Total Score

Figure 9: Attia ≥4

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Attia 2001 (USA)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort Study
Sampling: Authors did not disclose how
participant sampling occurred
Patient selection: 0-18 year-old with signs
and symptoms of acute pharyngitis. All patients
who had received antibiotics therapy within 5
days and those who were previously enrolled
were excluded.

Was a consecutive or random sample of patients
enrolled?

Yes

Was a case-control design avoided?

No

Did the study avoid inappropriate exclusions?

Unclear

Could the selection of patients have introduced
bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 587
Mean age in years (SD): 6.7 years (± 3.9)
Presentation: Signs and symptoms of acute
pharyngitis
Setting: Emergency Department, Two pediatric
outpatient clinics
Exclusions: N = 27 patients

Are there concerns that the included
patients and setting do not match the
review question?

Low Concern

Index Test
Index tests

Attia Score: 0-5

All tests
A. Risk of Bias
Were the index test results interpreted without Yes
knowledge of the results of the reference
standard?
If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the
index test have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test, its Low concern
conduct, or interpretation differ from the
review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)

streptococcal pharyngitis

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

throat culture and RADT
Is the reference standards likely to correctly
classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the results
of the index tests?

Yes

Could the reference standard, its conduct, Low risk
or its interpretation have introduced
bias?
C. Concerns regarding applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Uncertain of flow and timing of reference and index
tests

Was there an appropriate interval between
index test and reference standard?

Unclear

Did all patients receive the same reference
standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced
bias?

Low risk
Notes

Notes

Group A Streptococcus Prevalence: 37%
Clinical Predictors:
1) Scarlatiniform rash
2) Moderate to serve tonsillar swelling
3) Moderate to severe tenderness and enlargement of
cervical lymph nodes
4) Absence of moderate to severe coryza
No Clear course of action suggested

ba-Saddik 2014 (Yemen)
Patient Selection
A. Risk of Bias
Patient Sampling

Was a consecutive or random sample of
patients enrolled?

Design: Prospective cross-sectional
Sampling: Authors did not disclose how
participant sampling occurred
Patient selection: Children aged 1-16 years with
symptoms of a sore throat with evidence of fever,
anterior tonsillar exudates and anterior cervical
adenitis. Children who used antibiotics in the 2weeks prior were excluded.
No

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Was a case-control design avoided?

Yes

Did the study avoid inappropriate exclusions?
Could the selection of patients have
introduced bias?

Unclear
High risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 691
Mean age in years (SD): 11.3 years (±3.4)
Presentation: symptoms of a sore throat with
evidence of fever, anterior tonsillar exudates and
anterior cervical adenitis.
Setting: Children attending Elementary School
Exclusions: n = 39

Are there concerns that the included
patients and setting do not match the
review question?

High concern

Index Test
Index tests

McIsaac Score

All tests
A. Risk of Bias
Were the index test results interpreted without Unclear
knowledge of the results of the reference
standard?
If a threshold was used, was it pre-specified?

Yes

Could the conduct or interpretation of the High risk
index test have introduced bias?
Inherent bias of symptom scoring
B. Concerns regarding applicability
Are there concerns that the index test, its Low concern
conduct, or interpretation differ from the
review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)

streptococcal pharyngitis
throat culture and RADT

Is the reference standards likely to correctly
classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the results
of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target condition
as defined by the reference standard does
not match the question?

Low concern

Flow and Timing
A. Risk of Bias

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Flow and timing

Uncertain of flow and timing of reference and index
tests

Was there an appropriate interval between
index test and reference standard?

Unclear

Did all patients receive the same reference
standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced
bias?

Low risk

Notes

Group A Streptococcus Prevalence: 41.5%
McIsaac Clinical Predictors:
1) Temperature >38
2) No cough
3) Tender anterior cervical adenopathy
4) Tonsillar swelling or exudate
5) Age
Course of action:
0-1: No culture or antibiotic required
2-3: culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical
grounds

Notes

Breese 1977 (USA)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort
Sampling: Authors did not disclose how participant
sampling occurred
Patient selection: Authors did not disclose how
patients were selected

Was a consecutive or random sample of
patients enrolled?

No

Was a case-control design avoided?

Unclear

Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have
introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 670
Mean age in years (SD): Not reported
Presentation: Acute respiratory illness
Setting: Office-based

Are there concerns that the included
patients and setting do not match the
review question?

Unclear concern

Index Test
Index tests

Breese Score

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation of
the index test have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test,
its conduct, or interpretation differ
from the review question?

Unclear concern

Reference Standard
A. Risk of Bias
Target condition and reference standard(s) Streptococcal Pharyngitis
Throat Culture
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Are there concerns that the target
Low concern
condition as defined by the reference
standard does not match the question?
Flow and Timing
A. Risk of Bias
Flow and timing

Uncertain of flow and timing of reference and index
tests

Was there an appropriate interval between Unclear
index test and reference standard?
Did all patients receive the same reference Unclear
standard?
Were all patients included in the analysis?

Unclear

Could the patient flow have
introduced bias?

Unclear risk

Notes

Group A Streptococcus Prevalence: 54.2%
Breese Clinical Predictors:
1) Month patient is seen
2) Age
3) Leukocyte count
4) Fever
5, Sore throat

Notes

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

6) Cough
7) Headache
8) Abnormal pharynx
9) Abnormal cervical nodes
Course of action: No clear action suggested

Cohen 2012 (France)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort Study
Sampling: Secondary analysis of data from an office
based study (unpublished data)
Patient selection: 3-15 year old with a diagnosis of
pharyngitis and did not receive antibiotics for 7 days
before inclusion.

Was a consecutive or random sample of
patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 785
Mean age in years (SD): 6.1 (2.5)
Presentation: Diagnosis of pharyngitis
Setting: Office-based, multicenter
Exclusions: n = 22

Are there concerns that the included Low concern
patients and setting do not match
the review question?
Index Test
Index tests

McIsaac Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation of High risk
the index test have introduced bias?
Inherent bias of symptom scoring
B. Concerns regarding applicability
Are there concerns that the index test, Unclear concern
its conduct, or interpretation differ
from the review question?

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Reference Standard
A. Risk of Bias
Target condition and reference standard(s) streptococcal pharyngitis
throat culture and RADT
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Yes

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the
question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Some throat swabs were plated >48 hours after
collection. Prolonged or inadequate shipping conditions
could have resulted in the loss of viability of GAS.

Was there an appropriate interval between Unclear
index test and reference standard?
Did all patients receive the same reference Yes
standard?
Were all patients included in the analysis?

No

Could the patient flow have
introduced bias?

High risk

Notes
Notes

Group A Streptococcus Prevalence: 36.3%
McIsaac Clinical Predictors:
1) Temperature >38
2) No cough
3) Tender anterior cervical adenopathy
4) Tonsillar swelling or exudate
5) Age
Course of action
0-1: No culture or antibiotic required
2-3: culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical grounds

Cohen 2015 (France)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort Study
Sampling: Consecutive sampling

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Patient selection: 3-14 year olds with a diagnosis of
pharyngitis and did not receive antibiotics for 7 days
before inclusion.
Was a consecutive or random sample of
patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

Low risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 676
Mean age in years (SD): 6.1 (2.5)
Presentation: Diagnosis of pharyngitis
Setting: Office-based, multicenter
Exclusions: None reported

Are there concerns that the included
patients and setting do not match the
review question?

Low concern

Index Test
Index tests

Breese, McIsaac, Wald, and Attia Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Yes

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation
of the index test have introduced
bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test, Low concern
its conduct, or interpretation differ
from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s) streptococcal pharyngitis
throat culture and RADT
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Yes

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the
question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Some throat swabs were plated >48 hours after
collection. Prolonged or inadequate shipping conditions
could have resulted in the loss of viability of GAS.

Was there an appropriate interval between Unclear
index test and reference standard?
Did all patients receive the same reference Yes
standard?
Were all patients included in the analysis?

Yes

Could the patient flow have
introduced bias?

High risk

Notes
Notes

Group A Streptococcus Prevalence: 41.4%
The study reviewed 8 Prediction Scores. Only four were previously validated.
Breese Clinical Predictors:
(a) month patient is seen, (b) age, (c) leukocyte count, (d) fever, (e) sore
throat, (f) cough, (g) headache, (h) abnormal pharynx, (i) abnormal cervical
nodes
Wald Clinical Predictors:
(a) Age, (b) Fever, (c) adenopathy, (d)Pharyngitis, (e) no upper respiratory
symptoms
McIsaac Clinical Predictors:
(a) temperature >38, (b) no cough, (c) tender anterior cervical adenopathy,
(d) tonsillar swelling or exudate, (e) age
Attia Clinical Predictors:
(a) scarlatiniform rash, (b) moderate to serve tonsillar swelling, (c) moderate
to severe tenderness and enlargement of cervical lymph nodes, (d) absence of
moderate to severe coryza

Edmonson 2005 (USA)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Retrospective, cross-sectional
Sampling: Consecutive patients
Patient selection: <24 years of age and had a
diagnostic test to detect pharyngeal GAS.

Was a consecutive or random sample of
patients enrolled?

Yes

Was a case-control design avoided?

Yes

Did the study avoid inappropriate

Unclear

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

exclusions?
Could the selection of patients have
introduced bias?

High risk – retrospective chart review and included
some adults.

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 614
Mean age in years (SD): Not reported for all 614
patients
Presentation: Included patients had a diagnostic test
to detect pharyngitis
Setting: Single Pediatric Clinic
Exclusions: 605 patients excluded or not selected for
analysis

Are there concerns that the included
High concern
patients and setting do not match the Inherent bias of symptom scoring
review question?
Index Test
Index tests

McIssac Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Yes

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation of
the index test have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test, High concern
its conduct, or interpretation differ
from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s) streptococcal pharyngitis
RADT OR throat culture
Is the reference standards likely to
correctly classify the target condition?

Unclear

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Yes

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

High risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the question?

Unclear concern

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Flow and Timing
A. Risk of Bias
Flow and timing

Not discussed by the authors

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

No

Were all patients included in the analysis? No
Could the patient flow have
introduced bias?

High risk

Notes
Notes

Group A Streptococcus Prevalence: Not reported.
McIsaac Clinical Predictors:
1) Temperature >38
2) No cough
3) Tender anterior cervical adenopathy
4) Tonsillar swelling or exudate
5) Age
Course of action
0-1: No culture or antibiotic required
2-3: culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical grounds

Mazur 2014 (Poland)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort Study
Sampling: Author did not disclose how participant
sampling occurred
Patient Selection: 2-15 year old with signs and
symptoms suggesting of GAS etiology and had not had
pharyngitis for 3 months and were not treated with
antibiotics for 2 weeks.

Was a consecutive or random sample of
patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 90
Mean age in years (SD): 6.6 (3.4)
Presentation: symptoms suggesting of GAS etiology
Setting: Single site outpatient clinic

Are there concerns that the included Low concern
patients and setting do not match

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

the review question?
Index Test
Index tests

McIssac Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Yes

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation
of the index test have introduced
bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?

Low concern

Reference Standard
A. Risk of Bias
Target condition and reference
standard(s)

streptococcal pharyngitis
throat culture and RADT

Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the
reference standard does not match
the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported by the author

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

Yes

Were all patients included in the analysis? No
Could the patient flow have
introduced bias?

Unclear risk

Notes
Notes

Group A Streptococcus Prevalence: Not reported.

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

McIsaac Clinical Predictors:
(a) Temperature >38
(b) No cough
(c) Tender anterior cervical adenopathy
(d) Tonsillar swelling or exudate
(e) Age
Course of action
0-1: No culture or antibiotic required
2-3: culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical grounds

McIsaac 1998 (Canada)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort Study
Sampling: Authors did not report
Patient selection: All patients >3 with a new upper
respiratory tract infection (URTI)/pharyngitis and did not
receive antibiotics for 7 days prior or were
immunocompromised.

Was a consecutive or random sample of
patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 90 (3-14 year olds)
Mean age in years (SD): reported only as a range 314 year olds.
Presentation: URTI/Pharyngitis
Setting: Office-based, single center
Exclusions: 126 for bronchitis, otitis media, sinusitis,
pneumonia, Lower respiratory tract syndrome.

Are there concerns that the included
patients and setting do not match the
review question?

Unclear concern

Index Test
Index tests

McIsaac Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

No

Could the conduct or interpretation of

High risk

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

the index test have introduced bias?
B. Concerns regarding applicability
Are there concerns that the index test, Low concern
its conduct, or interpretation differ
from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s) streptococcal pharyngitis
throat culture
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
Low concern
condition as defined by the reference
standard does not match the question?
Flow and Timing
A. Risk of Bias
Flow and timing

Not discussed by authors

Was there an appropriate interval between
index test and reference standard?

Unclear

Did all patients receive the same reference
standard?

Yes

Were all patients included in the analysis?

No

Could the patient flow have introduced Unclear risk
bias?
Notes
Notes

Group A Streptococcus Prevalence: 35.5% for Children
McIsaac Clinical Predictors:
(a) Temperature >38
(b) No cough
(c) Tender anterior cervical adenopathy
(d) Tonsillar swelling or exudate
(e) Age
Course of action
0-1: No culture or antibiotic required
2-3: culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical grounds

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

McIsaac 2000 (Canada)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective cohort study, survey of physicians
Sampling: Authors did not report
Patient selection: All patients >3 with a new upper
respiratory tract infection (URTI)/Pharyngitis and did
not receive antibiotics for 7 days prior or were
immunocompromised.

Was a consecutive or random sample of
patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

Unclear risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 167 (3-14 year olds)
Mean age in years (SD): range reported - 3-14 year
olds.
Presentation: URTI/Pharyngitis
Setting: Multicenter outpatient
Exclusions: n = 71 because of other conditions

Are there concerns that the included
patients and setting do not match the
review question?

Unclear concern

Index Test
Index tests

McIsaac Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation of
the index test have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test,
its conduct, or interpretation differ
from the review question?

Low concern

Reference Standard
A. Risk of Bias
Target condition and reference standard(s) Streptococcal Pharyngitis
Throat Culture
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results

Unclear

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

interpreted without knowledge of the
results of the index tests?
Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
Low concern
condition as defined by the reference
standard does not match the question?
Flow and Timing
A. Risk of Bias
Flow and timing

Tests done at the same time

Was there an appropriate interval between Yes
index test and reference standard?
Did all patients receive the same reference Yes
standard?
Were all patients included in the analysis?

No

Could the patient flow have
introduced bias?

Low risk

Notes
Notes

Group A Streptococcus Prevalence: 34.8% for Children
McIsaac Clinical Predictors:
(a) Temperature >38
(b) No cough
(c) Tender anterior cervical adenopathy
(d) Tonsillar swelling or exudate
(e) Age
Course of action
0-1: No culture or antibiotic required
2-3: Culture all; treat only if result is positive
> 4: Culture all or treat with penicillin on clinical grounds

Orda 2016 (Australia)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Case-Control Study
Sampling: Convenience sample
Patient selection: 3-15 year olds presenting with
sore throats and already taking antibiotics

Was a consecutive or random sample of
patients enrolled?

No

Was a case-control design avoided?

No

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

High risk

B. Concerns regarding applicability

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Patient characteristics and setting

Sample Size: N = 248, n = 101 presenting with sore
throat
Mean age in years: 7.9
Presentation: Sore throat
Setting: Emergency Department
Exclusions: 2 parents refused cultures

Are there concerns that the included
patients and setting do not match the
review question?

Low concern

Index Test
Index tests

Centor Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation of
the index test have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index test, Low concern
its conduct, or interpretation differ
from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference standard(s) streptococcal pharyngitis
throat culture
Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the reference
standard does not match the
question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported by authors

Was there an appropriate interval between Unclear
index test and reference standard?
Did all patients receive the same reference Yes
standard?

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Were all patients included in the analysis?

Yes

Could the patient flow have
introduced bias?

Low risk

Notes
Notes

Group A Streptococcus Prevalence: 26% for Children
Centor Score:
(a) Absence of Cough
(b) Swollen and tender cervical lymph nodes
(c) Fever
(e) Tonsillar exudate or swelling
No clear action recommended

Roggen (Brussels)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Retrospective Cohort Study
Sampling: Chart review
Patient selection: 2-16 years old with diagnosis codes
for infectious mononucleosis, nasopharyngitis, tonsillitis,
and sore throat. Excluded patients included chronic
respiratory illness, cardiac, hematological or
immunological diseases, and children you had received
antibiotics.

Was a consecutive or random sample of
patients enrolled?

No

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have
introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 441
Mean age in years: 5 years
Presentation: 2-16 years old with diagnosis codes for
infectious mononucleosis, nasopharyngitis, tonsillitis, and
sore throat.
Setting: University Hospital
Exclusions: n = 1677

Are there concerns that the included Low concern
patients and setting do not match
the review question?
Index Test
Index tests

Centor Score

All tests
A. Risk of Bias
Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

If a threshold was used, was it prespecified?

Yes

Could the conduct or interpretation
of the index test have introduced
bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?

Low concern

Reference Standard
A. Risk of Bias
Target condition and reference
standard(s)

Streptococcal Pharyngitis
Throat Culture

Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the
reference standard does not match
the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported by author

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

Yes

Were all patients included in the
analysis?

Yes

Could the patient flow have
introduced bias?

Low risk

Notes
Notes

Group A Streptococcus Prevalence: 27.6% for Children
Centor Score:
(a) Absence of Cough
(b) Swollen and tender cervical lymph nodes
(c) Fever
(d) Tonsillar exudate or swelling
No clear action recommended

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Ulukol 2000 (Turkey)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort
Sampling: Not reported by authors
Patient selection: All Children diagnosed with
tonsillopharyngitis and excluded otitis media and sinusitis

Was a consecutive or random sample of Unclear
patients enrolled?
Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients have Unclear risk
introduced bias?
B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 716, n = 514 (3 years and older)
Mean age in years (SD): 7.4 (1.7)
Presentation: Tonsillopharyngitis
Setting: Single site, Hospital Outpatient
Exclusions: none reported

Are there concerns that the
included patients and setting do
not match the review question?

Low concern

Index Test
Index tests

Breese Score

Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

All tests
A. Risk of Bias

Could the conduct or interpretation High risk
of the index test have introduced
Inherent bias of symptom scoring
bias?
B. Concerns regarding applicability
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?

Low concern

Reference Standard
A. Risk of Bias
Target condition and reference
standard(s)

Streptococcal Pharyngitis

Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results

Unclear

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

interpreted without knowledge of the
results of the index tests?
Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target
condition as defined by the
reference standard does not match
the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported by authors

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

Yes

Were all patients included in the
analysis?

Yes

Could the patient flow have
introduced bias?

Low risk

Notes
Notes

Group A Streptococcus Prevalence: 31.3%
Breese Clinical Predictors:
(a) Month patient is seen
(b) Age
(c) Leukocyte count
(d) Fever
(e) Sore throat
(f) Cough
(g) Headache
(h) Abnormal pharynx
(i) Abnormal cervical nodes
Course of action: Score 30 or great definitive for positive streptococcal
pharyngitis

Wald 1998 (USA)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Prospective Cohort
Sampling: Not reported by author
Patient selection: Children 2-16 years of age with sore
throat and history of fever. Excluded if they had
received antibiotics therapy within the previous 7 days.

Was a consecutive or random sample of Unclear
patients enrolled?
Was a case-control design avoided?

Yes

Did the study avoid inappropriate

Unclear

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

exclusions?
Could the selection of patients have High risk
introduced bias?
B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 365
Mean age in years: 8.2 years
Presentation: Sore throat and history of fever
Setting: ED department or Children's Hospital walk-in
clinic
Exclusions: None reported by author

Are there concerns that the
included patients and setting do
not match the review question?

Unclear concern

Index Test
Index tests

Wald Score

Were the index test results interpreted
without knowledge of the results of the
reference standard?

Unclear

If a threshold was used, was it prespecified?

No

All tests
A. Risk of Bias

Could the conduct or interpretation High risk
of the index test have introduced
Inherent bias of symptom scoring
bias?
B. Concerns regarding applicability
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?

Low concern

Reference Standard
A. Risk of Bias
Target condition and reference
standard(s)

streptococcal pharyngitis
throat culture

Is the reference standards likely to
correctly classify the target condition?

Yes

Were the reference standard results
interpreted without knowledge of the
results of the index tests?

Unclear

Could the reference standard, its
conduct, or its interpretation have
introduced bias?

Low risk

B. Concerns regarding applicability
Are there concerns that the target Low concern
condition as defined by the
reference standard does not
match the question?

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported by authors

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

Yes

Were all patients included in the
analysis?

Yes

Could the patient flow have
introduced bias?

Low risk

Notes
Notes

Group A Streptococcus Prevalence: 48%
Wald Clinical Predictors:
(a) Age
(b) Fever
(c) Adenopathy
(d) Pharyngitis
(e) No upper respiratory symptoms
No clear action recommended

Walker 2006 (Egypt)
Patient Selection
A. Risk of Bias
Patient Sampling

Design: Retrospective Cohort Study
Sampling: Patients from previous study
Patient selection: Children with a history of sore throat
and unequivocal erythema of the pharynx, exclusion
included a history of rheumatic fever, antibiotic treatment
within 7 days, presence of another diagnosis requiring
antibiotic treatment or residence outside of Cairo.

Was a consecutive or random sample
of patients enrolled?

Unclear

Was a case-control design avoided?

Yes

Did the study avoid inappropriate
exclusions?

Unclear

Could the selection of patients
have introduced bias?

High risk

B. Concerns regarding applicability
Patient characteristics and setting

Sample Size: N = 410
Mean age in years: not reported
Presentation: history of sore throat and unequivocal
erythema of the pharynx
Setting: Single Site, Outpatient Clinic
Exclusions: None reported

Are there concerns that the
included patients and setting do
not match the review question?

Low concern

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Index Test
Index tests

Breese, Centor, Wald, McIsaac Score

All tests
A. Risk of Bias
Were the index test results
interpreted without knowledge of the
results of the reference standard?

Unclear

If a threshold was used, was it prespecified?

Yes

Could the conduct or
interpretation of the index test
have introduced bias?

High risk
Inherent bias of symptom scoring

B. Concerns regarding applicability
Are there concerns that the index Low concern
test, its conduct, or interpretation
differ from the review question?
Reference Standard
A. Risk of Bias
Target condition and reference
standard(s)

Streptococcal pharyngitis
Throat culture

Is the reference standards likely to
correctly classify the target
condition?

Yes

Were the reference standard results Unclear
interpreted without knowledge of the
results of the index tests?
Could the reference standard, its Low risk
conduct, or its interpretation
have introduced bias?
B. Concerns regarding applicability
Are there concerns that the
target condition as defined by
the reference standard does not
match the question?

Low concern

Flow and Timing
A. Risk of Bias
Flow and timing

Not reported

Was there an appropriate interval
between index test and reference
standard?

Unclear

Did all patients receive the same
reference standard?

Yes

Were all patients included in the
analysis?

Unclear

Could the patient flow have
introduced bias?

Unclear risk

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Notes
Notes

Group A Streptococcus Prevalence: 24.6%
The study reviewed 7 Prediction Scores. Only four were previously validated.
Breese Clinical Predictors:
(a) month patient is seen, (b) age, (c) leukocyte count, (d) fever, (e) sore
throat, (f) cough, (h) headache, (i) abnormal pharynx, (j) abnormal cervical
nodes
Wald Clinical Predictors:
(a) Age, (b) Fever, (c) adenopathy, (d)Pharyngitis, (e) no upper respiratory
symptoms
McIsaac Clinical Predictors:
(a) temperature >38, (b) no cough, (c) tender anterior cervical adenopathy, (d)
tonsillar swelling or exudate, (e) age
Centor Predictors:
(a) Absence of Cough, (b) Swollen and tender cervical lymph nodes, (c) Fever,
(d) Tonsillar exudate or swelling
No clear action recommended

If you have questions – please contact jmichael@cmh.edu or amyers@cmh.edu

Appendix B
Question 2: In pediatric patients, how often do adverse side effects occur with antibiotic therapy?
Question Originator: Strep Pharyngitis CPG Team
Plain Language Summary: The purpose of this review is to discuss the potential harm-to-benefit risk of prescribing antibiotics.
Antibiotics are among the most commonly prescribed medication, but up to half the time they are administered when not needed. Antibiotics are used to
treat infections, and are generally safe when used as directed. However, like taking any medication, there is risk in taking antibiotics. Few studies have
looked at the potential side effects. For example, adverse drug events that occur with amoxicillin (Lexicomp®, 2017) therapy are:
•
Commonly-nausea, vomiting, diarrhea, or rash
•
Less commonly- abdominal pain and lack of appetite
From a study published on children who were administered penicillin, one in 14 children experienced vomiting, diarrhea, or rash.

Literature Summary: The use of antibiotics is not without side effects and clinicians should make parents aware of the harm-to-benefit ratio of taking
antibiotics. For every 14 children treated with antibiotics, one child will have an adverse event such as vomiting, diarrhea, or rash.
Two systematic reviews citation and one retrospective review citation were included in this synopsis.
From a Cochrane systematic review and meta-analysis, children with acute otitis media who were treated with antibiotics had a significant increase in
adverse drug events (ADE) RR = 34%, 95% CI [16, 55] (see Figure 1). ADEs were defined as vomiting, diarrhea, or rash in this review (Venekamp et al.,
2013).
Bourgeois et al. (2009) obtained data from the National Center for Health Statistics, which collects information on patient visits to outpatient clinics and
emergency departments throughout the United States. Reporting on children from zero to 18 years of age from 1995-2005 who sought treatment for an
adverse drug event (ADE). Antibiotics were implicated in over a quarter of the ADEs, RR = 27.5%, 95% CI [21.5%, 34.5%]. Among ADEs related to
antimicrobial agents, more than half were the result of a penicillin (40%) or cephalosporin (15%). The most common manifestations were dermatologic
conditions (RR = 45.4%, 95% CI [36.9, 54.1]) and gastrointestinal symptoms (RR = 16.5%, 95% CI [11.1, 23.8])
Kuehn et al. (2015) completed a systematic review evaluating antibiotic associated diarrhea (ADD) in patients treated with penicillin or related antibiotics.
Forty-two studies were identified. Antibiotic treatment was for acute otitis media, sinusitis, pharyngitis, and pneumonia. Thirty-three trials reported on
amoxicillin/clavulanate, six on amoxicillin, and three on penicillin V (N=7729 children). Data was pooled for each type of penicillin. The overall average for
antibiotic associated diarrhea (AAD) was 17.2%. Although a definition of diarrhea was not clearly defined across the studies, the AAD incidence was
reported to be 19.8% for amoxicillin/clavulanate, 8.1% for amoxicillin, and 1.2% for penicillin V. A definition of diarrhea was not clearly defined across all
studies.
Search Strategy and Results: Search: ("Otitis Media"[Mesh] OR "otitis media"[tw] OR "Sinusitis"[tw] OR "Streptococcus pyogenes"[Mesh] OR
"Streptococcal Infections"[Mesh] OR "Streptococcal Infection*"[tw] OR "Streptococcus pyogenes"[tw] OR "group A strep"[tw] OR “group A
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streptococcal”[tw] OR “group A streptococcus”[tw] OR "streptococcal pharyngitis"[All Fields] OR "GAS pharyngitis"[All Fields]) AND (Exanthema[tw] OR
rash[tw] OR Nausea[tw] OR Vomiting[tw] OR Diarrhea[tw] OR "Drug Eruptions"[Mesh] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR
"Adverse Drug Reaction Reporting Systems"[Mesh] OR "adverse effects"[sh] OR "adverse effect*"[tw] OR "adverse reaction*"[tw] OR "Anti-Bacterial
Agents/adverse effects"[MAJR]) AND ("Amoxicillin"[tw] OR "Penicillin*"[tw]) AND (infant[tw] OR child[tw] OR childr*[tw] OR childh*[tw] OR adolescen*[tw]
OR pediatr*[tw] OR paeditr*[tw]) AND ("2011/12/01"[PDat] : "2017/12/31"[PDat])
Studies included in this review:
Venekamp et al., (2013)
Bourgeois et al. (2009)
Kuehn et al. (2015)
Excluded articles and reason for exclusion:
Author
Kaya et al., (2014)

Reason for exclusion
reports on allergies not side effects

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.3) (Higgins & Green, 2011) was used to synthesize the three included studies.
EBP Scholar’s responsible for analyzing the literature:
Hope Scott, RN, CPEN
Kori Hess, PharmD
Jennifer Foley, RT(R)(N), CNMT
Rhonda Sullivan, MS, RD, LD
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Jarrod Dusin, MS, RD, LD, CNSC
Date Developed: August 2017
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Included

Eligibility

Screening

Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b

Records identified through
database searching
(n = 37)

Additional records identified
through other sources
(n = 2)

Records after duplicates removed
(n = 39)

Records screened
(n =39)

Records excluded
(n = 35)

Full-text articles assessed
for eligibility
(n =4)

Full-text articles excluded,
with reasons
(n =1)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 3)

b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Figure 1.
Antibiotics versus placebo, adverse events (vomiting, diarrhea, or rash)
(Venekamp et al., 2013)
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Kuehn 2015
Methods
Background

Summary of reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials
Objective: Determine rate of antibiotic associated diarrhea (AAD).
Secondary Objective: determine dose and duration, diarrhea severity, age and size of study
population, length of post therapy follow up, number of children who discontinued therapy as a
result of AAD
Participants: Children who received oral penicillin therapy for any indicated infection
Completed study: N = 7729
Gender: Not reported
Age: 0-17 years

Methods

Inclusion criteria: received oral penicillin therapy for any indicated infection
Exclusion criteria: treatment related to chronic conditions, concomitant antimicrobial therapy,
dose not specified
Advanced search conducted in EMBASE and Medline for any article reporting on rates of AAD arising
from the use of any oral penicillin to treat an indicated infection in children 0-17 years.

Results

Included Studies: 42 clinical trials from Medline and EMBASE search (33 trials reported on
amoxicillin / clavulanate (amox/clav), 6 trials on amoxicillin (amox), 3 trials on penicillin)
Overall rate of AAD across all trials = 17.2%
• rate of ADD with amox/clav = 19.8%
o 4:1 formulation = 10.3-36.6%
o 7:1 formulation = 6.7-47.8%
o 8:1 formulation = 10-27%
o 14:1 formulation = 11-30%
• rate of AAD with amox = 8.1%
• rate of AAD with pen V = 1.2%
Dose and duration:
• amox/clav 40-90 mg/kg/day / 5.7-15 mg/kg/day for 5-14 days
• amoxicillin 40-90 mg/kg/day for 6-10 days
• penicillin 25-45 mg/kg/day for 10 days
Severity: not consistently defined but overall 55 cases of AAD were reported as severe
Duration of follow-up:
• amox 10-28 days
• amox/clav 4-46 days
• penicillin 14-28 days
Rate of discontinuation due to AAD (from studies specifically reporting reasons for
discontinuation):
• amox = 2 of 940
• amox/clav = 71 of 2926
• penicillin = 1 of 417

Discussion

Sources of bias: definition of diarrhea not well described across studies
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Bourgeois 2009
Methods
Background

Retrospective study on treatment of adverse drug events (ADEs)
Setting:
• Patient visits to outpatient clinics and emergency departments throughout the
United States.
• The data was obtained from the National Center for Health Statistics, which
collects information on patient visits to outpatient clinics and emergency
departments throughout the United States.
• They looked at children 0 to 18 years of age seeking medical treatment for an
Adverse Drug Events (ADE) between 1995 and 2005.
Number complete: 585,922 visits
% Male: 51.5
Inclusion criteria:
• Visits classified as an ADE with E-code for drugs
• medicinal or biological substances causing adverse effects in therapeutic use
• diagnosis of anaphylactic shock due to adverse effect of correct medicinal
substance properly administered
• an unspecified adverse effect to correct medicinal substance properly
administered
• shock due to anesthesia in which the correct substance was properly administered
• aspirin gastritis
• drug dermatitis
• drug reaction in newborn
• drug psychoses
• allergic uritcaria
• neuropathy due to drugs
• accidental poisoning by drugs
• poisoning by drugs
Exclusion criteria:
• ADE resulting from administration of wrong medication,
• intentional drug overdose, or
• use of illicit substance,
• drug dependence or abuse,
• drug withdrawal,
• intentional self-harm
• assault by poisoning.

Results

•
•
•

The medication classes most frequently implicated in an ADE were antimicrobial
agents 7.5%, 95% CI [21.5%, 34.5%].
Among ADEs related to antimicrobial agents, more than half were the result of a
penicillin (40%) or cephalosporin (15%).
The most common symptom manifestations were dermatologic conditions 45.4%,
95% CI [36.9%, 54.1%] and gastrointestinal symptoms 16.5%, 95% CI [11.1%,
23.8%].
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Appendix C
Question 3: In pediatric patients with group A streptococcal (GAS) pharyngitis, do oral antibiotics versus intramuscular (IM) injections result in faster clinical
cure?
Question Originator: Streptococcal Pharyngitis CPG Team
Plan Language Summary: The cure rate for oral and IM penicillin are both equivocal, therefore a strong recommendation is made that antimicrobials for
GAS pharyngitis may be given either orally or intramuscular.
Literature Summary: A strong recommendation is made based on strong evidence from a previously published guideline (Shulman et al., 2012).
A clinical practice guideline and one randomized control trial were identified related to oral versus intramuscular injections for the treatment of GAS
pharyngitis (Eslami et al., 2014; Shulman et al., 2012).
The Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Diagnosis and Management of GAS Pharyngitis, recommends antibiotics
be given either orally or intramuscular (Shulman et al., 2012). IDSA also recommended intramuscular benzathine penicillin G (BPG) therapy is preferred for
patients deemed unlikely to complete a full 10-day course of oral therapy. The guideline gave a strong recommendation and rated the evidence as strong.
An evidence table was not provided for this topic in the guideline.
A randomized control trial by Eslami et al. (2014) compared efficacy of once daily oral amoxicillin versus BPG in relieving various clinical manifestations and
the bacteriologic response to pharyngitis in 99 pediatric patients. In the amoxicillin group, 18.9% failed to respond to treatment compared to 6.4% in the
BPG group but the difference was not statistically significant (p=.10). Benzathine penicillin G was more effective at reducing cough (p= .01), abdominal
pain (p= .01), and reducing exudate (p= .01). There was no significant difference in reducing erythema (p> .05), reducing severity of cervical lymph node
tenderness and enlargement (p> .05), and reducing sore throat (p> .05).
Search Strategy and Results: The IDSA parent guideline was identified for this question (Shulman et al., 2012). A literature search was conducted from
December 2011-December 2017 to identify any current studies answering the clinical question.
(Pharyngitis[tw] OR Pharyngotonsillitis[tw]) AND (penicillin[tw] OR amoxicillin[tw] OR "drug therapy"[sh] OR "anti-bacterial agent"[tw] OR
therapy[tw] OR treatment[tw] OR antibiotic[tw] OR antibiotics[tw]) AND ("Streptococcal Infection*"[tw] OR "Streptococcus pyogenes"[tw] OR
("group A" AND streptoc*)) AND (infant[tw] OR child[tw] OR childr*[tw] OR childh*[tw] OR adolescen*[tw] OR pediatr*[tw] OR paeditr*[tw]) AND
("2011/12/01"[PDat] : "2017/12/31"[PDat])
Studies included in this review:
Shulman et al., (2012)
Eslami et al., (2014)
Studies not included in this review with exclusion rationale:
Author (Year)
Reason for exclusion
Altamimi et al., (2012)
Only oral medications reviewed
Armengol et al., (2012)
Only oral medications studied.
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van Driel et al., (2016)
Gidengil et al., (2013)
Kuroki et al., (2013)
Sarrell et al., (2012)

Intramuscular injections not reviewed
Study did not compare Intramuscular injections versus oral
Only oral medications studied
Study did not compare Intramuscular injections versus oral

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize the one included study.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cohcrane Collaboration, 2011.

EBP Scholar’s responsible for analyzing the literature:
Helen Murphy, BHS RRT AE-C
EBP team member responsible for reviewing, synthesizing, and developing this document:
Jarrod Dusin, MS, RD, LD, CNSC
Date Developed: August 2017
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Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b

Records identified through
database searching
(n = 14)

Additional records identified
through other sources
(n = 0)

Included

Eligibility
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Records after duplicates removed
(n = 14)

Records screened
(n = 14)

Full-text articles assessed
for eligibility
(n = 7)

Records excluded
(n = 7)

Full-text articles excluded,
with reasons
(n = 6)

Studies included in
qualitative synthesis
(n = 1)

b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Elsami 2014
Methods
Participants

RTC
Setting: Academic hospital in North-East Iran, Mashhad
Randomized into study: (only positive throat cultures) :N=99
Group 1: 750mg orally once-daily amoxicillin (amoxicillin) for 10 days n=68
Group 2: Single IM injection of benzathine penicillin G (BPG) n=31
Five hundred and seventy one children with pharyngitis met the enrollment criteria
Four hundred and seventy two had negative throat culture
Ninety nine had positive throat cultures
Gender, males: n=51
Age, years:
Group 1: mean 8.4 +/- 1.6
Group 2: mean 9.1 +/- 1.5
Inclusion criteria:
• Children 6-15 years presented with pharyngitis (sore throat, erythema, exudate, tender or
enlarged anterior cervical lymph nodes) before the initiation of drug therapy
• GAS positive throat culture
Exclusion criteria:
• Reporting of one or more of the following:
o Oral antibiotic use within preceding week
o Intramuscularly administered antibiotics within 28 days prior to visit
o No signs of pharyngitis
o Negative throat culture for GAS
o History of allergy to the drugs
Power analysis:
• at least 97 children with GAS positive for p-value <0.05, CL 95% and permissible error 1%

Interventions

Outcomes
Results

Both Groups:
• Evaluated for inclusion criteria
• Randomized into groups
• Given treatment
• Sent home from school after beginning treatment
Group 1: 750 mg orally once-daily amoxicillin for 10 days
Group 2: single shot of BPG 600,000 IU for children > 27 kg and 200.000 IU for children less than
27 kg
Primary: Compare efficacy of once-daily oral amoxicillin and BPG in relieving various clinical
manifestations and their bacteriologic response to pharyngitis.
▪
▪
▪
▪
▪
▪

In the amoxicillin group, 18.9% failed to respond to treatment compared to 6.4% in the
penicillin group.
BCG was more effective at reducing cough and abdominal pain (p=.01)
BCG was more effective in reducing exudate (p=.01)
No significant difference in reducing erythema was found between the two drugs (p> .05)
No significant difference in reducing severity of cervical lymph nodes, tenderness, and
enlargement was found between the two drugs (p> .05)
No significant difference in reducing sore throat was found between the two drugs (p>
.05).

Sore throat
Group 1: Before: n=52, After: n=4
Group 2: Before: n=29, After: n=3
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Erythema
Group 1: Before: n=51, After: n=31
Group 2: Before: n=30, After: n=12
Exudate
Group 1: Before: n=39, After: n=18
Group 2: Before: n=24, After: n=0
Lymph nodes
Group 1: Before: n=46, After: n=13
Group 2: Before: n=22, After: n=15
Failed to respond
Group 1: failed to respond 18.9%
Group 2: failed to respond 6.4%
Risk of bias table
Bias

Authors'
judgement

Support for judgement

Random sequence generation
(selection bias)

Unclear Risk States random allocation, but not discussed how it was done.

Allocation concealment
(selection bias)

Unclear Risk Not discussed

Blinding of participants and
personnel (performance bias)

High Risk

Physician not blinded, does not discuss if subject blinded

Blinding of outcome
assessment (detection bias)

High Risk

Physician not blinded and he assessed symptom outcomes in both
groups

Incomplete outcome data
(attrition bias)

High Risk

Did not report drop-out

Selective reporting (reporting
bias)

Clinical manifestations were not clearly defined, not sure if any were not
Unclear Risk reported. Also, reported on socio economic status but it was not
described objectively.

Other bias

Unclear Risk
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Appendix D
Question 4: In pediatric patients with streptococcal pharyngitis, is amoxicillin versus other antibiotics more efficacious for clinical cure?
Question Originator: Streptococcal Pharyngitis GPG Team

Plain Language Summary: Group A streptococcus (GAS), is the most common cause of bacterial pharyngitis, or sore throat, in children and adolescents.
While most sore throats are caused by viruses, for some individuals bacteria is the source of the throat infection. When GAS is the cause of a sore throat,
penicillin or amoxicillin are the treatments of choice (Shulman et al., 2012)
Literature Summary: Amoxicillin is as efficacious as other antibiotics, therefore a strong recommendation is made that amoxicillin or penicillin be used for
group A streptococcus A (GAS) pharyngitis. This recommendation is made based on very low quality evidence.
In the clinical practice guideline by the Infectious Diseases Society of America (Shulman et al., 2012), penicillin and amoxicillin are the recommended
treatments for GAS.
Outcome: Clinical cure rate 2 to 13 days follow-up
Six trials (N = 1165) report on clinical cure rate, measured between 2 to 13 days post the start of treatment of amoxicillin versus other antibiotics (Cohen
et al., 1996; Eslami et al., 2014; Feder, Gerber, Randolph, Stelmach, & Kaplan, 1999; Kuroki et al., 2013; Lennon, Farrell, Martin, & Stewart, 2008;
Shvartzman, Tabenkin, Rosentzwaig, & Dolginov, 1993) (see Table 1).
•
One study compared amoxicillin versus clavulanate/amoxicillin (n = 119) (Kuroki et al., 2013),
•
Three studies compared amoxicillin versus penicillin V (n = 790) (Cohen et al., 1996; Feder et al., 1999; Lennon et al., 2008),
•
One study compared amoxicillin versus phenoxymethylpenicillin (n = 157) (Shvartzman et al., 1993), and
•
One study compared amoxicillin verses benzathine penicillin G (n = 99) (Eslami et al., 2014).
The analysis of the studies showed no difference between treatments, RR 1.02, 95% CI [.96 to 1.02], (see Figure 1). A sub-group analysis of amoxicillin
versus clavulanate/amoxicillin showed a higher cure rate for amoxicillin at follow-up, RR = 1.24, 95% CI [1.04 to 1.48]. A sub-group analysis between the
three other antibiotics showed no difference between treatments: (a) amoxicillin versus benzathine penicillin G, RR = 0.86, 95% CI [.75 to 1.00]; (b)
amoxicillin versus penicillin V, RR = 1.01, 95% CI [.96 to 1.06]; (c) amoxicillin versus phenoxymethylpenicillin, RR = 1.04, 95% CI [.96 to 1.12]. The
studies were very low quality evidence due to the serious risk of bias and very serious inconsistency. Only one study (Lennon et al., 2008) did not have
some form of serious bias. There was substantial heterogeneity as evidenced by an I2 of 53%. The heterogeneity was likely due to different control
antibiotics and clinical cure follow-up times.
Outcome: Clinical cure rate 14 to 36 days follow-up
Four trials (N = 1300) reported on clinical cure rate for amoxicillin versus other antibiotics (14 to 36 days post start of treatment) (Feder et al., 1999;
Lennon et al., 2008; Shvartzman et al., 1993; NCT00643149) (see Table 1).
•
Two studies compared amoxicillin versus penicillin V (n = 470) (Feder et al., 1999; Lennon et al., 2008),
•
One study compared amoxicillin versus phenoxymethylpenicillin (n = 157) (Shvartzman et al., 1993), and
•
One study compared amoxicillin verses azithromycin (n = 673) (NCT00643148).
The analysis of the studies showed no difference between treatments, RR = 1.03, 95% CI [.96 to 1.1] (see Figure 2). A sub-group analysis (see Figure 2)
between the other antibiotics showed no difference between treatments, amoxicillin versus azithromycin G, RR =1.21, 95% CI [.97 to 1.51]; amoxicillin
versus penicillin V, RR = .99, 95% CI [.93 to 1.04]; amoxicillin versus phenoxymethylpenicillin RR = 1.06, 95% CI [1.00 to 1.13]. The studies were very
low quality evidence based on the serious risk of bias within the studies and a very serious inconsistency between studies. There was substantial
heterogeneity as evidenced by an I2 of 60%. The heterogeneity was likely due to different control antibiotics and clinical cure? follow-up times.
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Outcome: Adverse events
Three trials (n = 1077) reported on adverse events for amoxicillin versus other antibiotics (Cohen et al., 1996; Kuroki et al., 2013; NCT00643148) (see
Table 1).
•
One study compared amoxicillin versus clavulanate/amoxicillin (n = 86) (Kuroki et al., 2013),
•
One study compared amoxicillin versus penicillin V (n = 318) (Cohen et al., 1996), and
•
One study compared amoxicillin versus azithromycin (n = 318) (NCT00643148).
The analysis of the studies showed less adverse events with amoxicillin when compared to other antibiotics, OR = .35, 95% CI [.23 to .52] (see Figure 3). A
sub-group analysis showed no difference in adverse events was found between amoxicillin versus penicillin V, OR = .48, 95% CI [.14 to 1.63]. A sub-group
analysis of amoxicillin versus clavulanate/amoxicillin showed lower adverse events with amoxicillin OR = .17, 95% CI [.06 to .50]. Also, amoxicillin versus
azithromycin showed lower adverse events with amoxicillin, OR = 0.37, 95% CI [.25 to .56]). The studies were very low quality evidence due to the serious
risk of bias, inconsistency, and imprecision. The inconsistency was due to the studies measuring adverse events differently and imprecision was based on
the low number of events.
Search Strategy and Results: (Pharyngitis[tw] OR Pharyngotonsillitis[tw]) AND (penicillin[tw] OR amoxicillin[tw] OR "drug therapy"[sh] OR "antibacterial agent"[tw] OR therapy[tw] OR treatment[tw] OR antibiotic[tw] OR antibiotics[tw]) AND ("Streptococcal Infection*"[tw] OR "Streptococcus
pyogenes"[tw] OR ("group A" AND streptoc*)) AND (infant[tw] OR child[tw] OR childr*[tw] OR childh*[tw] OR adolescen*[tw] OR pediatr*[tw] OR
paeditr*[tw]) AND ("2011/12/01"[PDat] : "2017/12/31"[PDat])
Studies included in this review:
Cohen et al., (1996)
Eslami et al., (2014)
Feder et al., (1999)
Kuroki et al., (2013)
Lennon et al., (2008)
NCT00643148, (2004)
Shvartzman et al., (1993)
Studies not included in this review with exclusion rationale:
Author (Year)
Reason for exclusion
Swaminathanom et al., (2014)
Amoxicillin not included (cohort)
Schwartz, et al., (2015)
Different outcomes (cohort)
Gidengil, et al., (2013)
Amoxicillin alone (cohort)
Sarrell, et al., (2012)
Amoxicillin alone (cohort)
Armengol et al. (2012)
Amoxicillin alone (cohort)
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011)a was used to synthesize the seven included studies. GRADEpro
GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cohcrane Collaboration, 2011.
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Date Developed/Updated: November 2017
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b
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b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Table 1
Summary of Findings
Amoxicillin compared to other antibiotics for pediatric patients with streptococcal pharyngitis
Certainty assessment
№ of
Risk
participants of
(studies)
bias
Follow-up

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
Study event rates (%)
bias
certainty
of
With
evidence With
other
Amoxicillin
antibiotics

Relative Anticipated absolute
effect
effects
(95%
Risk with Risk
CI)
other
difference
antibiotics with
Amoxicillin

Clinical Cure (follow up: range 2 days to 13 days)
1165
(6 RCTs)

serious very serious

b

not serious

not serious

none

⨁◯◯◯
VERY
LOW

480/572
(83.9%)

572/593
(96.5%)

RR 1.02
(0.96 to
1.02)

839 per
1,000

17 more
per 1,000
(34 fewer
to 17 more)

not serious

not serious

none

⨁◯◯◯
VERY
LOW

382/651
(58.7%)

402/649
(61.9%)

RR 1.03
(0.93 to
1.10)

587 per
1,000

18 more
per 1,000
(41 fewer
to 59 more)

not serious

serious

none

⨁◯◯◯
VERY
LOW

123/542
(22.7%)

51/535
(9.5%)

OR 0.35 227 per
(0.23 to 1,000
0.52)

a

Clinical Cure (follow up: range 14 days to 36 days)
1300
(4 RCTs)

serious very serious

c

a

Adverse Events
1077
(3 RCTs)

serious serious f
d

e

134 fewer
per 1,000
(164 fewer
to 95
fewer)

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
Explanations
a. Only one study did not have some form of serious bias.
b. Substantial heterogeneity as evidence by an I2 of 53%. This is likely due to different control antibiotics and different follow-up times.
c. Substantial heterogeneity as evidence by an 12 of 60%. This is likely due to different control antibiotics and different follow-up times.
d. All three studies had high risk of bias and/or unclear risk.
e. Low number of events
f. Adverse events measured differently
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Figure 1
Comparison: amoxicillin versus other antibiotics, Outcome: clinical cure at 2 to 13 days
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Figure 2
Comparison: amoxicillin versus other antibiotics, Outcome: clinical cure 14 to 36 days
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Figure 3
Comparison: amoxicillin versus other antibiotics, Outcome: adverse events

If you have questions regarding this Specific Care Question – please contact jmichael@cmh.edu or amyers@cmh.edu

Office of Evidence Based Practice (EBP)
Figure 4
Risk of bias table
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Cohen 1996
Methods
Participants

Randomized control trial
Setting: Pediatric Physician offices in France between September 1993 and February
1995.
Randomized into study: N = 321
• Group 1 (Amoxicillin): n = 161
• Group 2 (Penicillin): n =160
Completed Study (tolerability): N = 318
• Group 1 (Amoxicillin): n = 160
• Group 2 (Penicillin): n = 158
Completed Study (efficacy day 4): N = 277
• Group 1 (Amoxicillin): n = 141
• Group 2 (Penicillin): n = 136
Completed Study (efficacy day 30): N = 216
• Group 1 (Amoxicillin): n = 111
• Group 2 (Penicillin): n = 105
Gender, males:
• Group 1 (Amoxicillin): n = 83 (51.9%)
• Group 2 (Penicillin): n = 70 (44.3%)
Age, years (mean):
• Group 1 (Amoxicillin): 5.9 (SD = 2.1)
• Group 2 (Penicillin): 5.9 (SD = 2.3)
Inclusion Criteria:
• Children of both sexes and 3 to 15 years old who had signs of
tonsillopharyngitis (tonsillopharyngeal erythema and/or exudate, with sore
throat or dysphagia, or fever >=38°C)
• A positive result in a rapid test for streptococcal antigen (Testpack Strept®;
Abbott Diagnostics, Rungis, France)
• A throat culture positive for group A streptococcus
Exclusion Criteria:
• Antibiotic treatment within 7 days before enrollment
• History of hypersensitivity to beta-lactams
• Severe underlying disease
• Previous inclusion in the study
Power Analysis: The authors did not disclose power analysis

Interventions

•
•
•

Group 1: oral amoxicillin (AMX) suspension, 50 mg/kg/day divided twice
daily for 6 days
Group 2: oral phenoxymethyl penicillin suspension (PEN V), 45 mg/kg/day
divided into three doses/day (75,000 IU/kg/day) for 10 days.
The only other authorized treatment was with antipyretic agents
(paracetamol or aspirin). If signs and symptoms persisted or adverse events
occurred, an additional visit was scheduled 3 to 5 days after the beginning of
treatment. A daily diary card was used by the parents to record temperature,
gastrointestinal disorders, compliance with treatment and concomitant
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medications.
Outcomes

Notes

Primary outcome(s):
• Eradication of pretreatment GAS on throat cultures obtained 4 days after the
completion of treatment
Secondary outcome(s)
• Efficacy and safety, 30-Day follow up
Limited information was reported for the outcomes at the 30-Day follow-up

Risk of bias table
Bias

Scholars’
judgement

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Unclear risk

Selective reporting (reporting
bias)

Unclear risk

Other bias

Unclear risk

Support for judgement
Centralized telephonic computer program
Centralized telephonic computer program
No blinding mentioned, blinding unlikely to affect the outcome.
Microbiologic studies and molecular typing were carried out by
personnel unaware of the treatment arm.
Per protocol analysis and no power analysis.
The data from the 30-day visit was limited
The study was supported by a grant from a pharmaceutical company

Eslami 2014
Methods
Participants

Randomized control trial
Setting: Education organization in North-East of Iran, Mashhad
Randomized into study: N = 571
Group1: Positive throat culture n = 99
Group 2: Negative throat culture n = 472
Completed Study Group 1 (only positive throat cultures): N = 98
Group 1A: 750mg orally once-daily amoxicillin (amox) for 10 days n = 68
Group 2A: Single shot of benzathine penicillin G (BPG) 600.000 IU and 200.000 IU
for children less than 27kg n = 31
Gender, males: 225
Group 1: 51
Group 2: 174
Age, years: (Mean + SD)
Group 1: 8.4 + - 1.6
Group 2: 9.1 + - 1.5
Inclusion criteria:
• Children 6-15 years presented with pharyngitis (sore throat, erythema,
exudate, tender or enlarged anterior cervical lymph nodes) before the
initiation of drug therapy
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• GAS positive throat culture
Exclusion criteria:
• Reports of one or more of the following:
o Oral antibiotic use within preceding week
o Intramuscularly administered antibiotics within 28 days prior to visit
o No signs of pharyngitis
o Negative throat culture for GAS
o History of allergy to the drugs
Power analysis:
• At least 97 children with GAS positive for p-value <.05, CL 95% and
permissible error 1%
Interventions

Both Groups:
• Evaluated for inclusion criteria
• Randomized into groups
• Given treatment
• Sent home from school after beginning treatment
Group 1A: 750 mg orally once-daily amoxicillin (amox) for 10 days
Group 2A: single shot of benzathine penicillin G (BPG) 600.000 International Units
and 200.000 International Units for children less than 27 kg

Outcomes

Notes

Primary:
Compare the efficacy of once-daily orally amoxicillin and BPG in relieving various
clinical manifestations and their bacteriologic response to pharyngitis
Group 1A:
• Sore throat
o before: 52% (64.2)
o after: 4% (57.1)
• Erythema
o before: 51 % (63)
o after: 31% (72)
• Exudate
o before: 39% (61.9)
o After: 18% (100)
• Lymph nodes
o before: 46% (67.6)
o after: 13% (46.4)
• Failed to respond 18.9%
Group 2A:
• Sore throat
o before: 29% (35.8)
o after: 34% (42.9)
• Erythema
o before: 30% (37.5)
o after: 12% (27.9)
• Exudate
o before: 24% (38.1)
o After: 0 (zero)
• Lymph nodes
o before: 22% (32.4)
o after: 15% (53.6)
• Failed to respond 6.4%
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Risk of bias table
Bias

Scholars’
judgement

Random sequence generation
(selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

High risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Unclear risk

Other bias

Unclear risk

Support for judgement
Not discussed
States random allocation, but not discussed
Physician not blinded, does not discuss if subject blinded
Physician not blinded and he assessed symptom outcomes in both
groups
Per protocol
In primary outcome clinical manifestations was not defined, so not
sure if any were not reported, reported on socio-economic status

Feder 1999
Methods
Participants

Randomized controlled trial
Setting: Private pediatric office in Danbury, Connecticut during the winter and spring
of 1996 to 1997
Randomized into study: N = 161
• Amoxicillin: n = 84
• Penicillin V: n = 77
Completed study: N = 152
• Amoxicillin: n =79
• Penicillin V: n =73
Gender, males (%) : Not stated in study
• Amoxicillin: 65%
• Penicillin V: 62%
Age, years (mean): 9.9
• Amoxicillin: 9.0
• Penicillin V: 11.4
Inclusion criteria
• Children between ages of 3-18 years old
• Clinical findings suggesting GABHS pharyngitis
Exclusion criteria
• History of hypersensitivity to penicillin or amoxicillin
• Patient who had received antimicrobial therapy within the previous week
Power analysis: Study did not state

Interventions

Experimental: Received Amoxicillin 750 mg (250 mg/5 ml suspension) orally once
daily for 10 days
Control: Received Penicillin V 250 mg (250 mg/5 ml suspension) orally three times
daily for 10 days
*Any participant having a positive throat culture on the follow up cultures after
completion of initial therapy was given Penicillin V 250 mg (250 mg/5 ml suspension)
orally three times daily for 10 days as a second round of treatment.
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Outcomes

Notes

Primary outcomes:
1) Eradication of group A, beta-hemolytic streptococcal (GABHS) pharyngitis from
the upper respiratory tract 18-24 hours after beginning therapy
2) Impact on the clinical course at days 4-6 and 14-21
3) Bacteriologic treatment failure rate
Secondary outcome: Newly acquisition GABHS
Bacteriologic treatment failures were defined as the presence of the same serotype of
GABHS on either follow-up cultures (4-6 days or 14-21 days after completing
therapy) as on the initial throat culture, regardless of clinical status. Patient with a
different serotype of GABHS on follow-up culture than the initial culture were
considered to have a newly developed GABHS rather than treatment failure.

Risk of bias table
Bias

Scholars’
judgement

Support for judgement

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Physicians were blinded to which treatment was being dispensed to
participants

Blinding of participants and
personnel (performance bias)

Low risk

Testing of throat cultures were done at a separate facility. Study did
not state where the rapid testing was done.

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Used table of random numbers

All testing for this study was done at a separate facility.
Per protocol analysis. They assigned 161 into the study but only
reported on 152
Reported on all primary outcomes stated.

Unclear risk

Kuroki 2013
Methods
Participants

Randomized control trial
Setting:
Multi-center study, Japan.
Randomized into study: N = 119
• Group 1 Clavulanate/amoxicillin (CVA/AMX): n = 64
• Group 2 Amoxicillin (AMX) n = 55
Completed Study: N = 93
• Group 1 (CVA/AMX): n = 52
• Group 2 (AMX) n = 41
Gender, males:
• Group 1 (CVA/AMX): n = 25 (46.3%)
• Group 2 (AMX) n = 22 (51.2%)
Age, years range (mean):
• Group 1 (CVA/AMX): 2-13y (5.6y)
• Group 2 (AMX): 1-9y (5.3y)
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Inclusion Criteria:
• Children with pharyngolaryngitis or tonsillitis aged less than 15 years, who
tested positive on the instantaneous Group A Streptococcus infection
diagnosis kit between November 2009 and May 2011
Exclusion Criteria:
• None provided
Power Analysis: The authors did not disclose power analysis.
Interventions

• CVA/AMX group: 3-day treatment with a combined clavulanate/amoxicillin
preparation (CVA/AMPC)(Clavamox combination dry syrup for pediatric) at a dose
level of 96.4 mg/kg/day (CVA 6.4 mg/kg/day, AMPC90 mg/kg/day) in two divided
doses
• AMX group: 10-day treatment at a dose level of 30 mg/kg/day in three divided
doses
Each patient was followed for approximately 1–2 weeks after completion or
discontinuation of treatment.

Outcomes
Notes

Primary outcome: Bacteriological efficacy
Safety outcome: Adverse reactions
•
•
•
•

There was no sign of abnormality or of acute glomerulonephritis in any
patient.
Urticaria and eruption (one case each) were noted in the CVA/AMX group,
and upper airway inflammation (one case) was seen in the AMX group.
None of these adverse reactions was severe.
Discontinuation of test drug treatment because of an adverse reaction
occurred in one patient (urticaria) from the CVA/AMX group and one patient
(diarrhea) from the AMX group.

Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholars’
judgement
Unclear risk

Allocation concealment
(selection bias)

High risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Unclear risk

Selective reporting (reporting
bias)

Low risk

Other bias

High risk

Support for judgement
Two groups by simple randomizations.
Concealment was not described by the authors
Not blinded, open-label.
Not blinded, but the outcome measurement is not likely to be
influenced by the lack of blinding (temperature, bacterial test,
urinalysis)
They used per protocol analysis
All outcomes were reported
The lead author received financial aid from Glaxo- SmithKline K.K.

Lennon 2008
Methods
Participants

Randomized, parallel-group, non-inferiority
Setting: single site (school-based clinic) in New Zealand from May 1996 to
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November 1998
Randomized into Study: N = 353
• Group 1: Amoxicillin QD n = 177
• Group 2: Penicillin V BID n = 176
Completed Study: N = 335
• Group 1: n = 166
• Group 2: n = 169
Gender, males (%):
• Group 1: 52%
• Group 2: 49%
Age, years (mean):
• Group 1: 8.7 years
• Group 2: 8.5 years
Inclusion criteria: Children presenting to a sore throat clinic at a primary school
and Auckland, New Zealand with signs and symptoms of acute pharyngitis (core temp
>38C, headache, nausea or abdominal pain, difficulty in swallowing, inflamed or
infected throat, tender glands in neck) AND had throat swab cultures positive for
GABHS
Exclusion criteria: Hypersensitivity to penicillin, were likely to require treatment
with other antimicrobials during the study period or had received antimicrobial
therapy within 72 h prior to study entry, had a previous history of acute rheumatic
fever, cardiac disease or kidney disease, had a rash suggestive of scarlet fever or
mononucleosis, were immunocompromised, had a neoplastic disease, a terminal
illness or neutropenia (absolute neutrophil count ,1.5610/9 cells/l) or had previously
been included in this study within the current school term (approximately 12 weeks
in duration)
Power Analysis: With no difference in treatment effect in the two arms of the trial
and assuming 85% eradication, 155 evaluable subjects per treatment group would
have 80% power to demonstrate noninferiority.
Interventions

Group 1: Amoxicillin 1500 mg by mouth once daily (or 750 mg if < 30 kg) for 10
days
Group 2: Penicillin V 500 mg by mouth twice daily (or 250 mg if < 20 kg) for 10
days

Outcomes
Notes

Eradication of GABHS determined with follow-up throat cultures on days 3-6, 12-16,
and 26-36
Positive follow-up throat cultures were further divided to differentiate between
treatment failure, relapse, or new acquisition.
Adherence rates were similar between treatment groups (based on direct observation
and/or diary analysis)
Study was completed at a single site in New Zealand which limits generalizability of
results

Risk of bias table
Bias

Scholars’
judgement

Support for judgement
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Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Groups were not blinded to treatment arm but this is unlikely to
affect the primary outcome: eradication of bacterial agent

Blinding of outcome
assessment (detection bias)

Unclear risk

No discussion of whether the study personnel reading the culture
results were blinded to treatment groups

Incomplete outcome data
(attrition bias)

Low risk

Reasons for lost data were reported and were similar between
treatment groups

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Computer generated randomization schedule
Allocation implemented by third party via telephone

Pre-specified outcomes were reported as expected
Funded by New Zealand Heart Foundation (no role in study design,
implementation, or interpretation)

NCT00643149
Methods
Participants

Randomized control trial, non-inferiority
Setting: Multicenter: 33 centers in North America (6 sites in Canada, 19 in US),
Latin America (3 sites in Costa Rica, 1 in Guatemala), and India (4 sites); Pediatric
outpatients; May 14, 2003 to May 23, 2004.
Number of participants randomized: N = 693
Number of evaluated (treated) participants: N = 673
Group 1: Azithromycin n = 337
Group 2: Amoxicillin n = 336
Number of participants discontinued: N = 125
Group 1: Azithromycin n = 56
Group 2: Amoxicillin n = 69
Age: Children 2 to 12 years
Gender: Not reported
Inclusion criteria: Acute pharyngitis/tonsillitis based on “erythematous pharyngeal
mucosa or thick exudate covering the pharynx and tonsillar area, and at least one of
the following signs or symptoms: sore/scratchy throat; pain on swallowing; chills
and/or fever; cervical adenopathy;
scarlet fever rash on the face and skin folds, or red tongue with prominent papillae
(”strawberry tongue“).”
- Positive rapid antigen detection test or positive culture for GABHS
- GABHS pharyngitis/tonsillitis (tested for susceptibility to azithromycin and
amoxicillin)

Interventions

Outcomes

Notes

Group 1: Azithromycin SR 60 mg/kg single dose (n = 337); bacteriological per
protocol population (n = 245)
Group 2: Amoxicillin 45 mg/kg twice daily for 10 days (n = 336); bacteriological per
protocol population (n = 237)
- Bacteriological cure (primary outcome)
- Clinical success
- Compliance
- Adverse events
- Time points of assessment: “Test of Cure” at 24 to 28 days after starting study
drug;
and long-term follow-up on days 38 to 45
Report provided by Pfizer
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- Study supported and conducted by Pfizer
- Protocol No: A0661071
- Outcomes only reported for “Bacteriological Per Protocol Population”, i.e. positive
GABHS culture at recruitment or within 48hrs of starting treatment, at least 8 days of
study medication and assessment at baseline
Risk of bias table
Bias

Scholars’
judgement

Random sequence generation
(selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)
Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)

Selective reporting (reporting
bias)
Other bias

Low risk
Unclear risk
High risk

Unclear risk
High risk

Support for judgement
Not reported
Not reported
Placebo matched to active treatment
Not reported
In total 693 randomized; 20 were not treated due to insufficient drug
supply at study site (no more information given). Of 673 patients
treated 125 patients discontinued (56 in azithromycin group and 69
in amoxicillin group); reasons for discontinuation provided (more
dropout due to adverse events in azithromycin arm (4.7% versus
.9%) and more lack of efficacy in amoxicillin arm (8.3% versus
3.3%)).
All outcomes reported
Study supported and conducted by Pfizer

Shvartzman1993
Methods
Participants

Randomized controlled trail
Setting: Five family medicine practices over six months in Israel
Randomized into study: N = 393 presented with symptoms suggesting
streptococcal pharyngitis
• Group 1: Phenoxymethylpenicillin 250 mg x 3-4 daily
• Group 2: Amoxycillin once daily
Completed Study: N = 157 (Positive throat culture and completed 24-48 hour and
14 day follow-up)
• Group 1: n = 82
• Group 2: n = 72 (3 patients were treated with penicillin after another
positive throat culture after 24 hours)
Gender, males:
• Group 1: n = 35
• Group 2: n = 29
Age, years:
• 0-4: n = 11
• 5-10: n = 66
• 11-20: n = 45
• >20: n = 22
• Unknown age: n = 13

If you have questions regarding this Specific Care Question – please contact
jmichael@cmh.edu or amyers@cmh.edu

Office of Evidence Based Practice (EBP)
Inclusion Criteria:
• Patients presented with symptoms suggestive of group A hemolytic
streptococcal pharyngitis in whom had a positive throat swab culture
Exclusion Criteria:
• Younger than 3 years old without s/s for group A hemolytic streptococcal
pharyngitis AND negative throat swab culture
• Patients with a history of hypersensitivity to penicillin
• Received antibiotics within the previous 72 hours
• Chronic disease
• Personal or family history of rheumatic fever
Power Analysis: Not reported
Interventions

Outcomes

•
•

Group 1: Phenoxymethylpenicillin 250 mg x 3-4 daily for 10days
Group 2: Amoxycillin once daily for 10days

Primary outcome:
• Positive throat culture at day 2
• Positive throat culture at day 14
Secondary outcome(s)
• School or work missed

Notes
Risk of bias table
Bias

Scholars’
judgement

Random sequence generation
(selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

Unclear risk

Blinding of outcome
assessment (detection bias)

Unclear risk

Support for judgement
How patients were randomized was not described.
Not described by authors
Patients were not blinded and it is unlikely personnel was blinded.
Although, the outcome was objective and it is unclear if blinding
would have affected the results.
Not described by authors

Incomplete outcome data
(attrition bias)

High risk

Only included patients that completed 14 days of follow-up. Did not
address how many or if any patients in amoxycillin group was treated
with phenoxymethlypencillin.

Selective reporting (reporting
bias)

High risk

Any patient who had received amoxycillin and whose throat culture
yielded positive results at 24-48 hours or was not improved within
three days was immediately switched to a 10 day course of
phenoxymethylpenicillin. This may explain why there were no positive
result for amoxycillin group on day 14!

Other bias

Unclear risk

If you have questions regarding this Specific Care Question – please contact
jmichael@cmh.edu or amyers@cmh.edu

Office of Evidence Based Practice (EBP)
Appendix E
Question 5: In pediatric patients, what is the incidence of streptococcal A pharyngitis under three years of age?
Question Originator: Strep Pharyngitis CPG Team
Plain Language Summary from The Office of Evidence Based Practice: The Infectious Diseases Society of America (IDSA) guideline recommends
that diagnostic tests for GAS are not indicated for children <3 years old because the incidence of GAS is uncommon in this age group, and ARF is rare in
children <3 years old (Carapetis, Steer, Mulholland, & Weber, 2005; Shulman et al., 2012). A meta-analysis included in the IDSA guidelines reported
children <3 years of age had a low prevalence of GAS pharyngitis (10% to 14%) compared to school-aged children (37%) (Shaikh, Leonard, & Martin,
2010). However, it is reasonable to consider testing children <3 years of age if there is a household contact with a school-aged child with documented
streptococcal pharyngitis (Shulman et al., 2012).

Literature Summary: A strong recommendation is made against testing children less three years of age for GAS pharyngitis, based on very low quality
evidence.
Further research, if performed is likely to have an important influence on our confidence in the results (Table 1).
Testing for Group A Streptococcal (GAS) pharyngitis in children < 3years of age is not recommended due to the low prevalence of GAS and the low risk
of developing acute rheumatic fever (ARF) in this population.
AGREE II (Brouwers et al., 2010) was used to grade and evaluate the IDSA guideline (Shulman et al., 2012). Based on the AGREE II scores, the
guideline obtained an overall high quality rating. The IDSA guideline reports the prevalence of GAS pharyngitis is significantly lower for children <3 years
of age, ranging from 10% to 14% (Shulman et al., 2012). The GAS pharyngitis prevalence increases to as high as 25% for the <3 years of age
population when there is an infection within a family (Shulman et al., 2012). Typically, the IDSA guideline does not recommend testing for children <3
years of age, although, special considerations can be made if there is a close household contact.
A systematic review by Shaikh et al. (2010), included in the IDSA guideline, identified three studies (Feery, Forsell, & Gulasekharam, 1976; Gunnarsson,
Holm, & Söderström, 1997; Rimoin et al., 2005) that looked at the prevalence of GAS infection among children <5 years of age (N=964) who presented
with a sore throat. Four studies were identified (Edmond et al., 1996; Feery et al., 1976; Ginsburg et al., 1985; Gunnarsson et al., 1997) that looked at
prevalence of GAS among asymptomatic children (N=1036). The pooled prevalence of children presenting with sore throat (0 to 5 years of age) with GAS
was 24%, 95% CI [21, 26]. The pooled prevalence of asymptomatic children (<5 years of age) with GAS was 4%, 95% CI [1, 7]. The authors of the
meta-analysis reported scarcity of studies looking at preschool age children and a high level of heterogeneity (P < .001) between the studies. Authors
were only interested in the point prevalence of GAS, not the incidence of GAS overtime; longitudinal studies in which the same child was cultured
multiple times were excluded.
Vieira et al. (2006) reported on prevalence of Streptococcus pyogenes. Children from Sao Paulo and Porto Velho Brazil, including children enrolled in
daycare and those not enrolled in daycare (N = 200). In the children (N = 50), each from four different settings (nursery school children - Sao Paulo and
Porto Velho; non-institutionalized children - Sao Paulo and Porto Velho) had a mean age of 1 year 10 months, 1 year 11 months, 4 years 3 months, and
4 years 3 months, respectively. The prevalence in the youngest groups was 2% and 8%, whereas the prevalence in the older groups was 16% and 24%.
Wu et al. (2016) conducted a three-year GAS surveillance study in pediatric clinics within 36 Beijing hospitals. Compared to children aged 0–4 years,
those aged 5–14 years had a higher risk of outpatient visits for GAS culture-positive pharyngitis in each year (2551 vs. 815 cases per 100,000 children in
2012, 976 vs. 304 cases per 100,000 children in 2013, and 3419 vs. 932 cases per 100,000 children in 2014, p < 0.05). The GAS culture-positive rate
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was 1-3% for children aged 0-4, while the GAS culture-positive rate was 4.6-14.9% for 5-14 year old.

Search Strategy and Results:
((("Pharyngitis"[tw] OR "pharyngitis"[mesh] OR Pharyngotonsillitis) AND ("Streptococcus pyogenes"[Mesh] OR "Streptococcal Infections"[Mesh] OR
"Streptococcal Infection*"[tw] OR "Streptococcus pyogenes"[tw] OR "group A strep"[tw] OR “group A streptococcal”[tw] OR “group A
streptococcus”[tw])) OR "streptococcal pharyngitis"[All Fields] OR "GAS pharyngitis"[All Fields]) AND Incidence[tw] AND (infant[tw] OR child[tw] OR
childr*[tw] OR childh*[tw] OR adolescen*[tw] OR pediatr*[tw] OR paeditr*[tw])
Studies included in this review:
Shaikh, N., et al. (2010). "Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis." Pediatrics 126(3): e557e564.
Shulman, S. T., et al. (2012). "Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the
Infectious Diseases Society of America." Clinical infectious diseases: cis 629.
Vieira, F. M. J., et al. (2006). "Prevalence of Streptococcus pyogenes as an oropharynx colonizer in children attending daycare: a comparative study of
different regions in Brazil." Revista Brasileira de Otorrinolaringologia 72(5): 587-591.
Wu, S., et al. (2016). "Estimated burden of group a streptococcal pharyngitis among children in Beijing, China." BMC Infectious Diseases 16(1): 452.
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program (Higgins et al., 2011), Review Manager (RevMan 5.1.7) was used to synthesize the three included studies.
GRADEpro GDT (Guideline Development Tool) (Guyatt et al., 2008) is the tool used to create Summary of Findings Tables for this analysis. AGREE II was
used to assess the quality of the one included guideline (Brouwers et al., 2010).
EBP Scholar’s responsible for analyzing the literature:
Kim Robertson, MBA, MT-BC
Audrey Snell, MS, RD, CSP, LD
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Jarrod Dusin, MS, RD, LD, CNSC
Developed: June 2017
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Table 1
Question: In pediatric patients, what is the incidence of streptococcal A pharyngitis under three years of age?
Setting: ED/UCC
Incidence of streptococcal A pharyngitis under three years of age
Certainty assessment
№ of
Risk
participants of
(studies)
bias
Follow-up

Summary of findings

Inconsistency Indirectness Imprecision Publication Overall
Study event
bias
certainty rates (%)
of
With
evidence With
>3year <3year
old
old

Relative Anticipated absolute effects
effect
(95%
Risk with
Risk difference
CI)
>3year old with <3year old

Prevalence/Incidence
(7
very
very serious
observational serious
a
studies)

b

not serious

serious

c

none

⨁◯◯◯
VERY
LOW

The pooled prevalence of children (n=964) presenting with sore
throat (<5 years of age) with GAS was 24%, 95% [21,26]. The
pooled prevalence of asymptomatic children (n=1036) (<5 years
of age) with GAS was 4%, 95% CI [1,7] (Edmond et al., 1996;
Feery et al., 1976; Ginsburg et al., 1985; Gunnarsson et al.,
1997; Rimoin et al., 2005).
Prevalence in children (mean age 1.8 year -1.9 year) was 2-8%
compared to 16-24% of older children (mean age 4 years 3
months) (Vieira et al., 2006).
Wu et al. (2016) found children aged 0-4 had lower risks of
outpatient visits for GAS culture-positive pharyngitis compared
to 5-14 year old (2551 vs. 815 cases per 100,000 children in
2012, 976 vs. 304 cases per 100,000 children in 2013, and 3419
vs. 932 cases per 100,000 children in 2014, p < 0.05). The GAS
culture-positive rate was 1-3% for children aged 0-4, while the
GAS culture-positive rate was 4.6-14.9% for 5-14 year olds.

CI: Confidence interval
a. 4 of the 7 studies are case series which typically yields very low quality evidence.
b. High level of heterogeneity among patients. Patients are from different countries and different age groups were observed.
c. Results are imprecise when studies include relatively few patients and few events.
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Included

Eligibility

Screening

Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b

Records identified through
database searching
(n = 77)

Additional records identified
through other sources
(n = 1)

Records after duplicates removed
(n = 78)

Records screened
(n =78)

Records excluded
(n = 71)

Full-text articles assessed
for eligibility
One Study was a
systematic review with 4
studies
(n =7)

Full-text articles excluded,
with reasons
(n =0)

Studies included in
quantitative synthesis
(meta-analysis)
One study was a
Systematic review with 4
studies
(n = 7)

b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Shaikh
Methods
Participants

Meta-analysis
Articles on GAS pharyngitis or asymptomatic carriage in children who were younger than 18
years.
Number of Studies: 29 articles met the inclusion criteria.
•
18 References: asymptomatic children
•

14 References: children with sore throat

•

3 References: both

All Ages Children Presenting with Sore Throat: N=68,731
Younger than 5 years Presenting with Sore Throat: 964
All Ages Asymptomatic Children: N=9662
Younger than 5 years Asymptomatic Children: N=1036
Inclusion:
•
Article with reported data on the prevalence of GAS in children who presented to a
clinician for evaluation of sore throat.
•

Only studies that used throat cultures as the gold standard were included;

•

Studies in which rapid antigen tests were used were included only when specimens that
were negative on the rapid antigen test were sent for culture confirmation.

Exclusions:
•
Authors were only interested in the point prevalence of GAS, not the incidence of
GAS overtime; longitudinal studies in which the same child was cultured multiple
times were excluded.

Results

•

Did not specifically identify the Streptococcus as group A

•

Included only children who lived in isolated communities or residential homes,

•

reported on an unusual epidemic of GAS,

•

Included large proportion (>30%) of children who had received antibiotics before the
throat culture

•

Required children to have signs and symptoms other than sore throat (eg, required
fever).

•

We excluded studies that did not describe the exact signs and symptoms required for
patient enrollment.

Prevalence of GAS Infection Among Children Presenting With Sore Throat
All ages: Pooled prevalence 37%, 95 CI [32,43]
Younger than 5 years: Pooled prevalence 24%, 95 CI [21,26]
Prevalence of GAS carriage Among Asymptomatic Children
All ages: Pooled prevalence 12% 95 CI [9,14]
Younger than 5 y: Pooled prevalence 4% 95 CI[1,7]
There was significant heterogeneity (P<.001) among the estimates from the 14 studies that
reported data on the prevalence of GAS among children with sore throat.
Among asymptomatic children who were younger than 18 years there was significant
heterogeneity among the estimates from the studies (P <.001).

Vieira 2006
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Methods
Participants

Prospective study
Setting: Brazil
Participants: Children from Sao Paulo and Porto Velho Brazil, including children enrolled in
daycare and those not enrolled (N = 200). Fifty children each from 4 different settings (3
nursery schools and one pediatric outpatient center) were included.
Number Complete: 200
Age:
• Group I: 3months to 3years (mean: 1year 10months)

•

Group II: 6months to 3years (mean: 1year 11months

•

Group III: 1year to 8years (mean: 4years 3months)

•

Group IV: 1year to 8years (mean: 4years 3months)

% Male Subjects:
• Group I (nursery school children - Sao Paulo): 47%
• Group II (non-institutionalized children - Sao Paulo): 54%
• Group III (nursery school children - Porto Velho): 56%
• Group IV (non-institutionalized children - Porto Velho): 54%
Inclusion Criteria:
• Healthy children not older than 10 years old
• Normal ear, nose and throat exam
Exclusion Criteria:
• Use of antibiotic therapy in the last 15 days
• Previous tonsillectomy
• Eating within 2 hours before taking the sample
• Congenital or acquired immunodeficiencies
• History of persistent tonsillitis (2 or more events in 6 months or 4 events in 1 year)
Interventions

•
•
•

Outcomes

Four groups were identified (see above), two from nursery schools and two from
outpatient children's health centers (non-nursery schools).
Samples of oropharynx material were taken following a microbiologic protocol
identified in the study.
Samples in Sao Paulo occurred during the months of June and July (dry winter), and
during Sept and Oct in Port Velho (during the hot and humid periods).
Prevalence Streptococcus pyogenes
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Results

Positive prevalence Streptococcus pyogenes
Group I: 4 (8%)
Group II: 1 (2%)
Group III: 12 (24%)
Group IV: 8 (16%)

•
•
•
•
•

In Sao Paulo, Streptococcus pyogenes was present in 8% of cultures in children from the
nursery school group, and in 2% in the control group (outpatient health center),
demonstrating a significant statistical difference between the groups.
In Porto Velho, Streptococcus pyogenes was present in 24% of the nursery school group
samples, and in 16% of the control group samples (outpatient health center). No
statistical difference was found between these two.
A significant statistical difference was found between the control groups of the two cities
and between the nursery school groups as well, with a higher prevalence in both found in
Porto Velho.
Analysis of the samples from the two cities was done in separate labs but using the same
standardization of processes.
The authors mention that the older age group normally has more colonization by SBHGA
due to higher prevalence of social contact than the younger range.

Wu2016
Methods

Participants

Prospective study to view the incidence of clinical cases of pharyngitis and GAS culturepositive pharyngitis, and their outpatient visits among children aged 0–14 years in Beijing,
China
Setting: 36 hospitals within Beijing districts from 2011-2013 then 17 hospitals in 2014.
Age groups: age 0-4
age 5-14
Overall 0-14

Outcomes

Results

•

Cases of Scarlet Fever from GAS

•

Cases of Pharyngitis from GAS

•

Culture-positive rates of GAS

Number of clinical cases of scarlet fever from GAS surveillances
Age 0–4: 1158
Age 5-14: 231,007
Age 0-14: 2366
Number of clinical cases of pharyngitis from GAS surveillances
Age 0-4: 231,007
Age 5–14: 216,225
Overall(0–14): 447,232
Number of clinical cases of scarlet fever from National Notifiable Infectious Disease
Surveillance System (NNIDSS)
Age 0-4: 2366
Age 5-14: 6712
Overall (0-14): 9078
•

An average of 29,804.6 clinical cases of pharyngitis per 100,000 person-year
occurred among children age 0-14 years resulting in correspondingly 19519.0 (95 %
CI: 18516.7,20521.2) outpatient visits per 100,000 person-years from 2012 to 2014
in Beijing.
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•

On average, there were 2685.1 (95 % CI: 2039.6,3330.6) GAS culture-positive
cases of pharyngitis and 1652.7 (95 % CI: 1256.5,2049.0) outpatient visits per
100,000 person-years during the same period.

•

The estimated burden of GAS pharyngitis was significantly higher than that of scarlet
fever.

•

Compared to children aged 0–4 years, those aged 5–14 years had a higher risk of
outpatient visits for GAS culture-positive pharyngitis in all the 3 years (2551.3 vs.
815.8 cases per 100,000 children in 2012, 976.9 vs. 304 cases per 100,000 children
in 2013, and 3419.9 vs. 932.6 cases per 100,000 children in 2014, p < 0.05).

•

From 2012 to 2014, 9078 clinical cases of scarlet fever aged 0–14 years were
reported from NNIDSS in Beijing, 26.1 % of whom were children aged 0–4 years,
and 73.9 % were between the age of 5 and 14 years.

•

Total of 4093 clinical cases of scarlet fever and 447,232 ones of pharyngitis were
reported from GAS surveillances in Beijing.

•

Of the 4093 clinical cases of scarlet fever, 28.3 % were children aged 0–4 years and
71.7 % were between the age of 5 and 14 years.

•

Of the 447,232 clinical cases of pharyngitis, 51.7 % were children aged 0–4 years
and 48.3 % were between the age of five and fourteen years.
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Appendix F
Question 6: In pediatric patients with streptococcal pharyngitis, how soon can patients return to school after starting antibiotics?
Question Originator: Strep Pharyngitis CPG Team
Plain Language Summary: Group A streptococcus (GAS) is the most common cause of bacterial pharyngitis in children and adolescents. Children can
return to school or daycare after 12-24 hours of starting antibiotic therapy for a strep throat. Most of the studies identified for this review checked follow-up
throat cultures at 18-24 hours. Only one study was found that looked at follow-up throat cultures between 12 to 23 hours but most of the patients (74%),
in this study, were tested between 20 to 23 hours (Schwartz, Kim, Martin, & Pichichero, 2015).
The American Academy of Pediatrics recommends that children can return to school or child care after 12 hours of antibiotic treatment (American Academy
of Pediatrics, 2017).
The Center for Disease Control and prevention recommends that people with strep throat should stay home from work, school, or daycare until they no
longer have a fever and have taken antibiotics for at least 24 hours so they do not spread the infection to others (The Center for Disease Control, 2016).
Literature Summary: Based on very low quality evidence a weak recommendation is made that children can return to school or daycare after 12-24 hours
of starting antibiotics.
Outcome: Positive throat culture after starting antibiotics
Due to the inconstancy of the different antibiotic treatments a meta-analysis was not performed for this outcome.
Schwartz et al. (2015) evaluated 111 children with positive streptococci between 12 to 23 hours after receiving a single dose of amoxicillin. Participants
were randomized into two groups either to receive a second dose one hour before their return clinic visit on day two, or after their return clinic visit on day
two. Eighty-two patients (74%) had a second culture at 18 to 24 hours. Only two patients had throat cultures at 12 hours. Only 10 of 111 participants
continued to have a positive rapid antigen detection test (RADT) result, confirmed with an overnight throat culture. In 91%, CI [86, 96%] of the study
participants Group A streptococci were not detected on the day two throat specimen by RADT nor by culture. There was no significant different between the
positive culture between the two groups (see Table 1, Figure 2).
Randolph, Gerber, DeMeo, and Wright (1985) randomized 194 children with positive throat cultures to receive penicillin V (n = 68), cefadroxil (n = 70), or
placebo (n = 56). Throat cultures were checked approximately 18 to 24 hours after starting on medication. Only two patients of the penicillin V group and
two patients of the cefadroxil groups were found to have a positive culture 18 to 24 hours after starting either medication (see Table 1, Figure 3).
Feder, Gerber, Randolph, Stelmach, and Kaplan (1999) randomized 152 children with positive throat cultures to receive penicillin V (n = 73) or amoxicillin
(n = 79). Throat cultures were checked at 18 to 24 hours after starting on antibiotics. One patient in the penicillin V group and none in the amoxicillin group
were positive at 18 to 24 hours (see Table 1, Figure 4).
Snellman, Stang, Stang, Johnson, and Kaplan (1993) randomized 47 children with a positive throat culture to receive oral erythromycin (n = 15),
benzathine penicillin (n = 15), or penicillin v (n = 17). Additional throat cultures were obtained during three home visits within 24 hours after their initial
clinic visit. Twenty patients were cultured between 17 to 24 hours after initial treatment with nine (33%) patients found to be still positive. Twenty patients
were tested between 12 to 18 hours with eight (40%) continuing to test positive after the initial treatment. The mean time to a negative culture was 14.7 +
5.73 hours for oral erythromycin, 18.8 + 5.57 hours for benzathine penicillin, and 18.1 ± 5.66 hours for penicillin V. Time to negative culture was not
statistically significant between the different antibiotics (see Figures 3, 4, and 5). For The following antibiotic comparisons the mean difference (MD) were
as follows:
•
Oral erythromycin vs. benzathine penicillin, MD = -4.10, P = .05, 95% CI [-8.23, .03]
•
Oral erythromycin vs. penicillin V, MD = -3.40, P = .09, 95% CI [-7.38, .58]
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•

Benzathine penicillin vs. penicillin V, MD = .70, P = .73, 95% CI [-3.26, 4.66]

A cohort study (Gerber, Randolph, & DeMeo, 1987) of 128 children with positive throat cultures were started on penicillin V at the end of their initial visit.
Only 115 children had a follow-up culture at 18 to 24 hours. Of the patients cultured, six patients remained positive for GAS at 18 to 24 hours after the
start of antibiotic treatment.

Search Strategy and Results: ("strep throat" OR (("Streptococcal Infections"[Mesh] OR "Streptococcus pyogenes"[Mesh]) AND ("Pharyngitis"[Mesh])))
AND ("Schools"[Mesh] OR "Students"[MeSH] OR "return to school") AND ("2011/12/01"[PDat] : "2017/12/31"[PDat]
Studies included in this review:
Gerber et al., (1987)
Feder et al., (1999)
Randolph et al., (1985)
Schwartz et al., (2015)
Snellman et al., (1993)
Studies not included in this review with exclusion rationale:
Author (Year)
Reason for exclusion
Krober et al., (1985)
Follow-up cultures at 2 days
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011) a was used to synthesize five included study. GRADEpro GDT
(Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0 ed.): The
Cohcrane Collaboration, 2011.

EBP Scholar’s responsible for analyzing the literature:
Jennifer Foley, RT(R)(N), CNMT
Erin Lindhorst, MS, RD, LD
Hope Scott, RN, CPEN
Kelly Huntington, RN, BSN, CPN
EBP team member responsible for reviewing, synthesizing, and developing this document:
Jarrod Dusin, MS, RD, LD, CNSC
Date Developed: November 2017
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12hours compared to 24hours for returning to school after starting antibiotics
Certainty assessment
№ of
Risk
participants of
(studies)
bias
Follow-up

Inconsistency Indirectness Imprecision Publication Overall
bias
certainty
of
evidence

Summary of findings
Study event rates Relative
(%)
effect
(95%
With
With
CI)
24hours 12hours

Positive Cultures after starting antibiotics (follow up: range 12 Hours to 24 Hours)
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Anticipated absolute
effects
Risk with
24hours

Risk
difference
with
12hours

503
(4 RCTs)

serious serious

c

not serious

serious

d

none

a,b

⨁◯◯◯
Schwartz et al. (2015) evaluated 111 children with
VERY LOW positive streptococci at 12 to 23 hours after receiving a
single dose of amoxicillin. Only 10 of 111 participants
continued to have a positive rapid antigen detection test
(RADT) result, confirmed by overnight throat culture.
Eight two patients (74%) had their second culture at 18
to 24hours. Only two patients had throat cultures at 12
hours.
Randolph et al. (1985) randomized 194 children with
positive throat cultures to receive penicillin V (n=68),
cefadroxil (n=70), or placebo (n=56). Throat cultures
were checked at approximately 18 to 24hours after
starting on medication. Only two patients of the penicillin
V group and two patients of the cefadroxil were positive
at 18 to 24hours after starting both medications.
Feder et al. (1999) randomized 152 children with positive
throat cultures to receive penicillin V (n=73) or amoxicillin
(n=79). Throat cultures were checked at 18 to 24 hours
after starting on antibiotics. One patient in the penicillin V
group and none in the amoxicillin group were positive at
12 to 24hours.
Snellman et al. (1993) randomized 47 children with
pharyngitis and a positive throat culture to receive oral
erythromycin (n=15), benzathine penicillin (n=15), or
penicillin v (n=17). Additional throat cultures were
obtained during three home visits in the 24hours after
their initial clinic visit. 27 patients were cultured at 17 to
24 hours after initial treatment and nine were still positive
(33%). Twenty patients were tested at 12 to 18 hours.
Eight were positive (40%) after initial treatment.

Positive Cultures after starting antibiotics (follow up: range 18 Hours to 24)
115
serious not serious
a
(1
observational
study)

not serious

serious

d

none

⨁◯◯◯
A cohort study (Gerber et al., 1987) of 115 patients with
VERY LOW a positive throat culture were started on penicillin V at the
end of their initial visit. A follow-up visit at 18 to 24hours
found Six patients still positive for group A streptococci.

Table 1
a. Poor study design
b. Per protocol analysis
c. each study used different antibiotics
d. Studies include relatively few patients and few events
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Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b

Records identified through
database searching
(n =7)

Additional records identified
through other sources
(n = 6)

Records screened
(n =13)

Records excluded
(n = 7)

Eligibility

Full-text articles assessed
for eligibility
(n =6)

Full-text articles excluded,
with reasons
(n =1)

Included

Screening

Records after duplicates removed
(n = 13)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 5)

b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Figure 2
Forest plot of comparison: Three different antibiotic comparisons
Outcome: Positive cultures at 12 to 24hours
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Figure 3
Forest plot comparison: Oral erythromycin vs benzathine penicillin
Outcome: Mean time to negative culture

Figure 4
Forest plot comparison: Oral erythromycin vs penicillin V
Outcome: Mean time to negative culture

Figure 5
Forest plot comparison: Benzathine penicillin vs penicillin V
Outcome: Mean time to negative culture
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Figure 6
Risk of Bias Table for Randomized Control Trials
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Feder 1999
Methods
Participants

Prospective, randomized, controlled trial
Setting: Private pediatric office in Danbury, Connecticut during the winter and spring of
1996 to 1997
Randomized into study: N= 161
• Amoxicillin: n = 84
• Penicillin V: n = 77
Completed study: 152
• Amoxicillin: n =79
• Penicillin V: n =73
Gender, males (%): not stated in study
• Amoxicillin: 65%
• Penicillin V: 62%
Age, years (mean): 9.9
• Amoxicillin: 9.0
• Penicillin V: 11.4
Inclusion criteria
• Children between ages of 3-18 years old
• Clinical findings suggesting GABHS pharyngitis
Exclusion criteria
• History of hypersensitivity to penicillin or amoxicillin
• Patient who had received antimicrobial therapy within the previous week
Power analysis: Study did not state

Interventions

Experimental: Received Amoxicillin 750 mg (250 mg/5 ml suspension) orally once daily for
10 days
Control: Received Penicillin V 250 mg (250 mg/5 ml suspension) orally three times daily for
10 days
*Any participant having a positive throat culture on the follow up cultures after completion
of initial therapy was given Penicillin V 250 mg (250 mg/5 ml suspension) orally three times
daily for 10 days as a second round of treatment.

Outcomes

Notes

Primary outcomes:
1) Eradication of group A, beta-hemolytic streptococcal (GABHS) pharyngitis from the
upper respiratory tract 18-24 hours after beginning therapy
2) Impact on the clinical course at days 4-6 and 14-21
3) Bacteriologic treatment failure rate
Secondary outcome: Newly acquisition GABHS
Bacteriologic treatment failures were defined as the presence of the same serotype of GAS
on either follow-up cultures (4-6 days or 14-21 days after completing therapy) as on the
initial throat culture, regardless of clinical status. Patient with a different serotype of GABHS
on follow-up culture than the initial culture were considered to have a newly developed GAS
rather than treatment failure.
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Risk of bias table
Scholars’
judgement

Bias
Random sequence
generation (selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance
bias)

Unclear risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Unclear risk

Selective reporting
(reporting bias)

Unclear risk

Other bias

Unclear risk

Support for judgement
Used table of random numbers
Physicians were blinded to which treatment was being dispensed to
participants
Testing of throat cultures were done at a separate facility. Study did
not state where the rapid testing was done.
All testing for this study was done at a separate facility.
Per protocol analysis. They assigned 161 into the study but only
reported on 152
Reported on all primary outcomes stated.

Gerber 1987
Methods
Participants

Cohort study
Participants: Patients aged 3 to 21 years old with clinical finding suggestive of GABHS
pharyngitis.
Setting: University of Connecticut Health Center
Number enrolled: N = 188 patients
Number of patients with isolated GABHS: N = 128
Number of patients with follow-up culture at 18-24 hours: N = 115
Gender, males: Not identified in study
Age, years (mean): 3 to 21 (10.2)
Inclusion criteria: Not reported
Exclusion criteria: Not reported
Covariates Identified: Not reported

Interventions

Outcomes
Notes

•
•
•
•

All patients began penicillin V therapy at the end of their initial visit.
Patients were asked to return in18 to 24hours for a second culture.
Patients were instructed to continue for 10 full days.
Patients returned for an additional follow-up visit 14 to 16 days after initial visit.

Primary outcome: Number of patients enrolled who had isolated GABHS.
Results:
• Of the 188 patients from who throat cultures were obtained at the initial visit, GABHS
were isolated from 128 (68%)
• 115 of the 128 returned for follow-up cultures at 18 to 24 hours.
• 115 patients from whom throat cultures were obtained at the 18 to 24 hour follow-up
visit, GABHS were isolated from six (5%).

Randolph 1985
Methods

Randomized control trial
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Participants

Setting: Private, pediatric office, United States 1983-1984
Randomized into study: N = 260
• Group 1 (penicillin): n = 87
• Group 2 (cefadroxil): n = 92
• Group 3 (placebo): n = 81
Completed Study: N = 194
• Group 1 (penicillin): n = 68
• Group 2 (cefadroxil): n = 70
• Group 3 (placebo): n = 56
Gender, males:
• Not reported
Age, years (mean) (SD): 8.8
• Group 1: Not reported
• Group 2: Not reported
• Group 3: Not reported
The study states that the three treatment groups were comparable with respect to age, sex,
race, clinical findings, and duration of illness prior to initiation of treatment.
Inclusion Criteria:
• Children 2-20 years of age
• clinical findings suggestive of GABHS pharyngitis
Exclusion Criteria:
• Children with a history of hypersensitivity to either penicillin or cephalosporins
• Children who had received antibiotic therapy within the previous 72 hours
Power Analysis: The authors did not disclose power analysis

Interventions

•
•
•

Group 1: Penicillin V 250 mg/5 ml, orally, three doses over the next 24 hours
Group 2: Cefadroxil 250 mg/5 ml, orally, three doses over the next 24 hours
Group 3: Grape syrup placebo, orally, three doses over the next 24 hours

Parents were instructed to:
• Take the child's temperature every 4 hours during waking hours
• Note the rate of improvement in the child's clinical status
• Return in 18 to 24 hours with a fresh urine specimen and the medicine bottle they had
been given
All study patients were evaluated for
• The presence and severity of three objective signs
o Fever
o Cervical lymphadenitis as manifested by tender, enlarged lymph nodes
o Pharyngeal injection
• Three subjective symptoms
o Sore throat
o Headache
o Abdominal pain
Outcomes

Notes

Primary outcome(s):
• Positive culture at 18-24 hours
Secondary outcome(s)
• Resolution of objective and subjective clinical symptoms
The study did not list the numbers of the positive cultures for each group at the 18-24 hour

If you have questions regarding this Specific Care Question – jmichael@cmh.edu or amyers@cmh.edu

visit. This prohibited the comparison between the penicillin and cefadroxil.
"Approximately 3% of the penicillin-treated and cefadroxil-treated patients had positive throat
cultures for GABHS at the 18- to 24-hour follow-up visit, whereas 100% of the placebo-treated
patients had positive throat cultures at this visit."
Risk of bias table
Scholars’
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Randomization was performed by a study nurse, provider and parents
were not aware of the group to which they were assigned

Blinding of participants and
personnel (performance bias)

Low risk

The evaluating physician, parents, and patients were unaware of
which agent was dispensed.

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

All 194 children with positive throat cultures returned for the 18- to
24-hour follow-up evaluation

Selective reporting (reporting
bias)

High risk

The authors did not disclose specific data numbers for the individual
group outcomes. Unable to compare penicillin vs. cefadroxil for the
18-24 hour follow-up.

Other bias

Table of random numbers

Unclear risk

Schwartz 2015
Methods
Participants

Randomized control trial
Setting: One private primary care pediatric practice located in Virginia
Randomized into study: N = 135
•
They do not disclose the initial randomization into the two groups. Twenty children were
excluded, but it does not describe which group they are from.
Completed Study: N = 111
• Group 1: Group A (two doses): n = 60
• Group 2: Group B (Single dose): n = 51
Gender, males:
• Group 1: Group A (two doses): n = 32 (53.3%)
• Group 2: Group B (Single dose): n = 34 (66.7%)
Age, years (mean):
• Group 1: Group A (two doses): mean n = 7.0
• Group 2: Group B (Single dose): mean n = 6.5
Inclusion Criteria:
• Symptomatic children with sore throat who had pharyngeal erythema and a positive rapid
antigen detection test (RADT) result for group A streptococcus (GAS).
Exclusion Criteria:
• Noncompliance with the protocol (n = 10)
• Critical data not entered on work sheet (n = 7)
• Miscellaneous reasons (n = 7)
Power Analysis: The authors did not disclose power analysis

If you have questions regarding this Specific Care Question – jmichael@cmh.edu or amyers@cmh.edu

Interventions

All study children swallowed the initial dose of amoxicillin in the office immediately after signed
informed parental consent and received 1 bottle of amoxicillin suspension (400 mg/5 mL), weight
dosage based at 50 mg/kg/d, administered in a single daily dose.
Group A: On the following morning (day 2 of study), group A subjects were given the day 2 dose
by a parent at least 1 hour before arrival at the office.
Group B: Only received only the day 1 dose of amoxicillin and did not receive the day 2 dose until
after the office visit and the throat culture/RADT specimen was taken.

Outcomes

Primary outcome:
• Evaluating the necessity of the 24 hours of antibiotic treatment before returning to school.

Notes

•
•

29 patients (26%) had their second culture at 12 to 17 hours
82 patients (74%) had their second culture at 18 to 24 hours

Risk of bias table
Scholars’
judgement

Bias

Support for judgement

Random sequence generation
(selection bias)

Low risk

A table of random numbers divided consecutive enrollees into 2
groups: group A and B

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

Low risk

It is unlikely that blinding would have affected the outcome of RADT
or culture.

Blinding of outcome
assessment (detection bias)

Low risk

No blinding of the outcome assessment, but the outcome
measurement is not likely influenced by the lack of blinding.

Incomplete outcome data
(attrition bias)

High risk

Per protocol analysis performed, 18% of patients were excluded for
"miscellaneous reasons" or "critical data not entered on worksheet"

Selective reporting (reporting
bias)

High risk

The primary outcome was to evaluate the necessity of 24hour of
antibiotics before returning to school. Both groups received an initial
dose of amoxicillin and returned the next day. The only difference
between the groups was the timing of the second dose.

Other bias

Unclear risk

The author reported: "We cannot exclude the possibility that the
morning dose of amoxicillin in group A subjects resulted in a
temporary negative throat culture and/or RADT that later reverted to
positive on that day, as the peak concentration of the morning
amoxicillin dose waned.”

Allocation concealment not discussed

Snellman 1993
Methods
Participants

Randomized control Trial
Setting: Study was performed October 1988 to April 1989 and September 1989 to May 1990,
in the Pediatric department in the White Bear Lake Medical Center of Group Inc., Minnesota.
Randomized into study: N =49
• Group 1: Oral Penicillin (OP)=unclear
• Group 2: Oral Erythromycin Estolate (OE)=unclear
• Group 3: Intramuscular benzathine Penicillin G (BPG)= unclear
Completed Study: N = 47
• Group 1: Oral Penicillin (OP) n = 17
• Group 2: Oral Erythromycin Estolate (OE) n =15
• Group 3: Intramuscular benzathine Penicillin G (BPG) n = 15
*Data from 2 of the 49 are not included in the analysis because of a technical problem with the
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laboratory incubator rendering the convalescent cultures unevaluable. Did not disclose which
group
Gender, males:
• N =33 males (did not disclose group breakdown)
Age, years (mean):
• 8.9 years (did not disclose group breakdown)
Inclusion Criteria:
• Children -4 to 17 years of age
• Living within a 15-minute drive of the clinic
• Being available for three repeat home visits during the 24 hours after enrollment in the
study
Exclusion Criteria:
• Concurrent bacterial infection
• Allergy to the antibiotics used in the study
• Received oral antibiotics within the previous week or benzathine penicillin within the
previous month
Power Analysis: Not reported
Interventions

Group 1: Oral penicillin V, 250mg three times a day for 10 days
Group 2: Oral Erythromycin Estolate, 250 mg three times daily for 10 days
Group 3: Intramuscular Benzathine Penicillin G, 600,000 units if body weight <60 pounds and
1.2 million units if >60 pounds
The study nurse visited the patient at home three times during the subsequent 24 hours. The
times were dependent upon time of admission to the study.
Home visit involved: throat culture, recording of signs and symptoms, and the ingestion of each
oral dose of antibiotic was supervised
At 4 weeks, patient returned to clinic for blood specimen collection to measure convalescent
antibody studies

Outcomes

Notes

1. At what point in the first 24 hours after initiating antibiotic therapy do throat cultures
from patients with pharyngitis and positive throat cultures for GAS actually become
negative?
2. What percentage of treated children have a negative throat culture by the morning
after initiating antibiotic therapy, often before a full 24 hours of therapy?
3. Can the choice of antibiotic affect the time required for conversion to a negative throat
culture?
4. Does the presence of specific clinical signs or symptoms at initial examination assist the
clinician in deciding how quickly the culture will become negative?
5. Do the presence of signs or symptoms at the time a throat culture is performed help
predict the presence of group A streptococci on that specific culture?
6. Does an antibody response to streptococcal extracellular antigens such as streptolysin
O or DNase B correlates with the length of time on therapy for conversion to a negative
throat culture?
Culture plates that failed to yield any colonies of group A B-hemolytic streptococci after 72
hours of incubation were considered negative. This does not represent eradication of the
streptococci from the upper respiratory tract during the 24-hour period, but it reflects a
decreased number of viable organisms in the upper respiratory tract, and thus, suggests
decreased "contagiousness" of the patient.
The mean time intervals between culture 1 and:
• Culture 2: 6.5 + 2.9 hours
• Culture 3: 15.7 + 4.2 hours
• Culture 4: 23.2 + 1.6 hours
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Risk of bias table
Bias

Scholars'
judgement

Support for judgement

Random sequence generation (selection
bias)

Low risk

Allocation concealment (selection bias)

Unclear risk Did not disclose

Blinding of participants and personnel
(performance bias)

Unclear risk

Blinding of outcome assessment
(detection bias)

Unclear risk Examination of all culture plates was performed by the
study nurse and also at the streptococcal research
laboratory

Rolled a three-numbered die

Did not disclose

Incomplete outcome data (attrition bias) High risk

Data from 2 of the 49 are not included in the analysis
because of a technical problem with the laboratory
incubator rendering the convalescent cultures unavailable.
Did not disclose which group

Selective reporting (reporting bias)

Low risk

All outcomes were reported

Other bias

Low risk

The study appears to be free of other sources
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Appendix G
Education handouts

If you have questions regarding this Specific Care Question – jmichael@cmh.edu or amyers@cmh.edu

If you have questions regarding this Specific Care Question – jmichael@cmh.edu or amyers@cmh.edu

If you have questions regarding this Specific Care Question – jmichael@cmh.edu or amyers@cmh.edu

Caring for Your Child with Strep Throat
Key Point
Strep throat is a common cause of sore throat in kids. Antibiotics can help your child feel better within a few days.

Your Child’s Diagnosis
Strep throat is an infection caused by bacteria (a type of germ). The type of bacteria is called Group A streptococcus –
that is why it is called strep throat. Kids with strep throat have a sore throat, and can have trouble swallowing, fever,
headache, and swollen glands in the neck. They also might have belly pain, feel sick to their stomach, and throw up.
Strep throat is contagious (can be spread to others). It can spread:
•
When someone uses the same fork, spoon, or drinking glass as someone with strep throat.
•
When someone with strep throat coughs, sneezes, or touches his or her own mouth or nose and then touches
another person.
•
If someone with strep throat touches something (such as a doorknob) that others will touch.
Strep throat is most common in school-age kids. However, it can affect people of any age, especially those who have
close contact with school-aged kids.
The doctor talked to you and your child and did an examination. Strep throat is usually diagnosed by touching a
cotton swab to both tonsils and the back of the throat to test it for strep germs. Some doctors do a rapid strep test. If
this test is positive, strep germs are present in the throat. If the rapid strep test is negative, strep germs may not be
present in the throat. A regular throat culture is usually sent to the lab when a rapid strep test is negative, or
sometimes if a rapid test was not done. The throat culture looks at whether strep germs grow over the next few
days.
Strep throat is treated with antibiotics. The antibiotics will help your child feel better within a few days. Antibiotics also
keep the infection from spreading to others. Treatment also helps prevent other problems that strep throat can
sometimes cause.
After your child has been on antibiotics for at least 12 hours, he or she is no longer contagious.
Home Care Instructions
•
Be sure your child takes all of the antibiotic doses as prescribed, even if he or she is feeling better. This is the
best way to kill the harmful germs.
•
Encourage your child to drink lots of liquids and rest as needed.
•
If swallowing is so painful that eating solids is hard to do, try serving liquids and soft foods, like soups,
milkshakes, smoothies, ice pops, or ice cream.
•
Help your child avoid acidic drinks like orange juice and lemonade, which can irritate the throat.
•
If you child has pain or is uncomfortable from fever, a medicine may help your child feel better:
o For children under 6 months, you may give acetaminophen (brand names include Tylenol, Feverall,
and Panadol)
o For children over 6 months, you may give acetaminophen (brand names include Tylenol, Feverall, and
Panadol) OR ibuprofen (brand names include Advil, Motrin, and Q-Profen), if recommended by your
doctor.
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•
•
•

•

•
•

Do not give aspirin to your child or teen, as it has been linked to a rare but serious illness called Reye
syndrome.
If your child is 5 years or older and is not at risk for choking, he or she may find it soothing to suck on hard
candy.
Saltwater gargling may help your child feel more comfortable, but should be used only for kids older than 6
years. Mix ¼ teaspoon of salt in 8 ounces of warm water and have your child gargle and spit 4-6 times per
day.
To prevent the spread of strep throat and other illnesses, remind your child and other family members to:
o Wash their hands often with soap and water. Be sure to scrub for at least 20 seconds, rinse, and dry
thoroughly. If soap and water are not available, a hand sanitizer with at least 60% alcohol can be
used.
o Avoid sharing food, drinks, dishes, eating utensils, napkins, or towels with others. Wash dishes in hot,
soapy water.
o Cover their mouth and nose when coughing or sneezing. A tissue can be used and then thrown away
(wash hands afterward). If a tissue is not available, sneeze or cough into the elbow or upper arm, not
the hands.

Special Instructions
If your doctor did a regular throat culture, follow up as recommended.
As long as your child is feeling better and does not have fever, he or she may return to childcare or school the
morning after treatment is started.

Call Your Health Care Professional if….
Your child:
•
Can’t take the antibiotics as directed.
•
Gets worse or does not get better within 3 days of starting antibiotics.
•
Can’t swallow any food or drinks.
•
Develops a rash, ear pain, or other symptoms.
•
Still has fever after 2-3 days. Or your child’s fever goes away and then comes back.
•
Develops neck swelling, difficulty opening and closing the mouth, voice changes, or drooling.
•
Has pee that is red or tea-colored.
Go to the ER if…
Your child:
•
Appears dehydrated; signs include dizziness, drowsiness, a dry or sticky mouth, sunken eyes, crying with few
or no tears, or peeing less often (or having fewer wet diapers).
•
Is having trouble breathing.
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Caring for Your Child with a Sore Throat (Pharyngitis)
Key Point
Sore throats are common in children and rarely serious. Many can be treated with simple methods at home.

Your Child’s Diagnosis
Sore throats are usually caused by viruses, but also can be due to bacteria, repeated coughing or vomiting, allergies,
secondhand smoke, or other factors.
Your child might have a fever and the neck glands may swell, which is a sign that your child’s body is fighting off
germs. Sore throats caused by a virus tend to get better by themselves in 4-5 days and can last up to 2 weeks.
Home Care Instructions
•
For pain, a medication may help your child feel better:
o For children under 6 months, you may give acetaminophen.
o For children over 6 months, you may give acetaminophen OR ibuprofen as directed.
•
Do not give aspirin to your child or teen as it has been linked to a rare but serious illness called Reye
syndrome.
•
Offer your child plenty of warm or cold liquids; both can help to relieve discomfort.
•
Children 5 years and older may find relief by sucking on hard candy. Younger children should not be given
hard candy or lozenges because they could choke.
•
Saltwater gargling may bring some relief, but should be used only for children older than 6 years. Mix ¼
teaspoon of salt in 8 ounces of warm water and have your child gargle 4-6 times a day.
•
Offer your child soft foods that are easy to swallow. Avoid salty, spicy, crunchy, or acidic foods (like citrus
fruits), which can irritate a sore throat.
•
Let your child rest as needed.
Special Instructions
•
If your health care provider did a strep throat culture, you will be contacted if the results were positive.
Call Your Health Care Professional if…
Your child:
•
Develops pus in the back of the throat.
•
Is extremely tired.
•
Has throat pain that worsens.
•
Develops a rash.
•
Is unable to take liquids
•
If fever lasts greater than 3 days.
Go to the ER if….
•
Has difficulty swallowing or breathing.
•
Starts drooling.
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Appendix H
Power Plan

Unique Plan Description: EDP Sore Throat CPG EKM
Plan Selection Display: EDP Sore Throat CPG EKM
PlanType: ED/UCC
Version: 1
Begin Effective Date: 12/31/2100 00:00
End Effective Date: Current
Available at all facilities
Plan Comment: Following Rule Associated to this Plan:PP_FLEX_ED_SORE_THROAT
EDP Sore Throat CPG EKM
Nursing
Oral fluid challenge
IV placement
Respiratory
Oxygen/Pulse oximetry
Laboratory
Testing children <3 years old is generally not indicated, unless signs and symptoms consistent with strep throat
and close contact with strep(NOTE)*
Rapid Ag Strep Gp A
Continuous Medications/Fluids
NS fluid bolus
10 mL/kg, IV, IV Soln, 1 time only (DEF)*
20 mL/kg, IV, IV Soln, 1 time only
Medications
acetaminophen 160 mg/5 mL oral liquid
10 mg/kg, PO, 1 time only (DEF)*
15 mg/kg, PO, 1 time only
acetaminophen oral 325 mg tablet
10 mg/kg, PO, 1 time only (DEF)*
15 mg/kg, PO, 1 time only
ibuprofen 100 mg/5 mL oral suspension
10 mg/kg, PO, 1 time only
ibuprofen 100 mg oral tablet
10 mg/kg, PO, 1 time only
oxyCODONE 5 mg/5 mL oral solution
0.1 mg/kg, PO, 1 time only (DEF)*
0.15 mg/kg, PO, 1 time only
oxyCODONE 5 mg oral tablet
5 mg, PO, 1 time only (DEF)*
10 mg, PO, 1 time only
Preferred treatment for positive Rapid Antigen Detection Test (RADT)-see Pharyngitis CPG(NOTE)*
Alternative choice for positive Rapid Antigen Detection Test (RADT)(NOTE)*
penicillin G benzathine
600,000 unit, IM, 1 time only [Less Than 27 kg] (DEF)*
1,200,000 unit, IM, 1 time only [Greater Than or Equal To 27 kg]
*Report Legend:
DEF - This order sentence is the default for the selected order
GOAL - This component is a goal
IND - This component is an indicator
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INT - This component is an intervention
IVS - This component is an IV Set
NOTE - This component is a note
Rx - This component is a prescription
SUB - This component is a sub phase
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